<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005525.pub3" GROUP_ID="ENDOC" ID="145805031718295119" MERGED_FROM="" MODIFIED="2015-05-19 16:22:53 +0100" MODIFIED_BY="Bernd Richter" REVIEW_NO="R_I_07_1" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2015-05-19 16:22:53 +0100" MODIFIED_BY="Bernd Richter">
<TITLE MODIFIED="2015-04-15 14:01:02 +0200" MODIFIED_BY="[Empty name]">Zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance</TITLE>
<CONTACT MODIFIED="2015-05-19 16:22:53 +0100" MODIFIED_BY="Bernd Richter"><PERSON ID="9DA0FCBF82E26AA2007D5B6E4992F15C" ROLE="AUTHOR"><FIRST_NAME>Regina</FIRST_NAME><LAST_NAME>El Dib</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>eldib@fmb.unesp.br</EMAIL_1><EMAIL_2>re.lucci@terra.com.br</EMAIL_2><MOBILE_PHONE>+55 11 9999 6647</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Anaesthesiology</DEPARTMENT><ORGANISATION>Botucatu Medical School, Universidade Estadual Paulista (UNESP)</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu, São Paulo</CITY><ZIP>18603-970</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 9 9999 6647</PHONE_1><PHONE_2>+55 14 3880 1097</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-05-19 16:22:53 +0100" MODIFIED_BY="Bernd Richter"><PERSON ID="9DA0FCBF82E26AA2007D5B6E4992F15C" ROLE="AUTHOR"><FIRST_NAME>Regina</FIRST_NAME><LAST_NAME>El Dib</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>eldib@fmb.unesp.br</EMAIL_1><EMAIL_2>re.lucci@terra.com.br</EMAIL_2><MOBILE_PHONE>+55 11 9999 6647</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Anaesthesiology</DEPARTMENT><ORGANISATION>Botucatu Medical School, Universidade Estadual Paulista (UNESP)</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu, São Paulo</CITY><ZIP>18603-970</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 9 9999 6647</PHONE_1><PHONE_2>+55 14 3880 1097</PHONE_2></ADDRESS></PERSON><PERSON ID="51833037364259238498111213155944" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Orsi</FIRST_NAME><MIDDLE_INITIALS>LF</MIDDLE_INITIALS><LAST_NAME>Gameiro</LAST_NAME><POSITION>Physical Therapist</POSITION><ADDRESS><DEPARTMENT>Reabilitation Service</DEPARTMENT><ORGANISATION>Universidade Estadual Paulista (UNESP)</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu</CITY><ZIP>18618-970</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 14 38116049</PHONE_1><FAX_1>+55 14 38827845</FAX_1></ADDRESS></PERSON><PERSON ID="z1408121109207479219900475113029" ROLE="AUTHOR"><FIRST_NAME>Matheus</FIRST_NAME><MIDDLE_INITIALS>SP</MIDDLE_INITIALS><LAST_NAME>Ogata</LAST_NAME><EMAIL_1>mspogata@alunos.fmb.unesp.br</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anaesthesiology</DEPARTMENT><ORGANISATION>Botucatu Medical School, Universidade Estadual Paulista (UNESP)</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu, São Paulo</CITY><ZIP>18603-970</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON><PERSON ID="64422251167871786596110726124914" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Norma</FIRST_NAME><MIDDLE_INITIALS>SP</MIDDLE_INITIALS><LAST_NAME>Módolo</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Professor</POSITION><EMAIL_1>nmodolo@fmb.unesp.br</EMAIL_1><MOBILE_PHONE>+ 55 14 9743 0211</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Anaesthesiology</DEPARTMENT><ORGANISATION>Botucatu Medical School, Universidade Estadual Paulista (UNESP)</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu, São Paulo</CITY><ZIP>18603-970</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 14 3811 6222</PHONE_1><FAX_1>+55 14 3811 6222</FAX_1></ADDRESS></PERSON><PERSON ID="63244373969461906135120112173208" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Leandro</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Braz</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>lbraz@fmb.unesp.br</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anaesthesiology</DEPARTMENT><ORGANISATION>Botucatu Medical School, Universidade Estadual Paulista (UNESP)</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu, São Paulo</CITY><ZIP>18603-970</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+ 55 14 3811 6222</PHONE_1></ADDRESS></PERSON><PERSON ID="93309029996319030844110923175908" ROLE="AUTHOR"><FIRST_NAME>Eliane</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Jorge</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>elianej@fmb.unesp.br</EMAIL_1><ADDRESS><DEPARTMENT>Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery</DEPARTMENT><ORGANISATION>Botucatu Medical School, Universidade Estadual Paulista (UNESP)</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu</CITY><ZIP>18618-970</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 14 9708 4050</PHONE_1></ADDRESS></PERSON><PERSON ID="z1211151020271031194113164573258" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Paulo</FIRST_NAME><LAST_NAME>do Nascimento Junior</LAST_NAME><EMAIL_1>pnasc@fmb.unesp.br</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anaesthesiology</DEPARTMENT><ORGANISATION>Botucatu Medical School, Universidade Estadual Paulista (UNESP)</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu, São Paulo</CITY><ZIP>18603-970</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+ 55 14 3811 6222</PHONE_1><FAX_1>+ 55 14 9778 3075</FAX_1></ADDRESS></PERSON><PERSON ID="2ABFAD7082E26AA2010AB3F2AA240E36" ROLE="AUTHOR"><FIRST_NAME>Vânia</FIRST_NAME><LAST_NAME>Beletate</LAST_NAME><EMAIL_1>vaniabeletate@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Nutrition</DEPARTMENT><ORGANISATION>University of São Camilo</ORGANISATION><ADDRESS_1>Rua Luiz Razera 22, apto 144</ADDRESS_1><ADDRESS_2>Nova America</ADDRESS_2><CITY>Piraciacaba SP</CITY><ZIP>13 417 530</ZIP><REGION>Sao Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 (19) 9743 2375</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-04-23 12:59:46 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="2" MONTH="3" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="3" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-05-18 11:40:38 +0200" MODIFIED_BY="Gudrun Paletta">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-04-15 15:25:33 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>This review is an update of the previous Cochrane systematic review (<LINK REF="REF-Beletate-2007" TYPE="REFERENCE">Beletate 2007</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-05-18 11:40:38 +0200" MODIFIED_BY="Gudrun Paletta">
<DATE DAY="8" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>The two new included studies, <LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK> and <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK>, did not change our conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-13 09:29:12 +0200" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT MODIFIED="2014-04-17 14:10:29 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Brazilian Cochrane Center</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-05-19 16:53:06 +0200" MODIFIED_BY="Bernd Richter">
<SUMMARY MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<TITLE MODIFIED="2013-10-02 08:29:26 +0200" MODIFIED_BY="[Empty name]">Zinc supplementation for the prevention of type 2 diabetes mellitus</TITLE>
<SUMMARY_BODY MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Review question</B>
</P>
<P>What are the effects of zinc supplementation compared with placebo or no treatment for the prevention of type 2 diabetes in adults with insulin resistance?</P>
<P>
<B>Background</B>
</P>
<P>Some studies have shown that zinc improves glucose levels (glycaemic control) in people with diabetes. As a consequence of diabetes long-term complications may develop, such as kidney, nerve and eye disease. Also, the risk of cardiovascular complications like heart attacks and strokes is raised. Type 1 diabetes is a form of diabetes where the body cannot produce insulin any more. The risk of developing type 2 diabetes increases with age, obesity and lack of physical activity and is characterised by an increasing inability of the body to make good use of insulin (insulin resistance). The mineral zinc plays a key role in the action of insulin and theoretically zinc supplementation used by people with insulin resistance could prevent the onset of diabetes.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We included three randomised controlled studies with a total of 128 participants in this review. The duration of zinc supplementation ranged between four and 12 weeks.</P>
<P>
<B>Key results</B>
</P>
<P>No study reported on our patient-important key outcomes (new onset of type 2 diabetes mellitus, side effects, health-related quality of life, all-cause mortality, diabetic complications, socioeconomic effects). The effects of zinc supplementation are uncertain regarding insulin resistance and lipid levels in the blood (mainly cholesterol and triglycerides).</P>
<P>
<B>Quality of evidence</B>
</P>
<P>The overall quality of the included studies was unclear because study authors did not provide important information for us to judge how the studies were performed (unclear risk of bias in most cases). In addition, the number of studies and participants is low and the study authors did not investigate important outcomes such as new onset of type 2 diabetes mellitus or side effects of zinc supplementation.</P>
<P>
<B>Currentness of evidence</B>
</P>
<P>This evidence is up to date as of March 2015.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<ABS_BACKGROUND MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Diabetes is associated with long-term damage, dysfunction and failure of various organs, especially the eyes, kidneys, nerves, heart and blood vessels. The risk of developing type 2 diabetes increases with age, obesity and lack of physical activity. Insulin resistance is a fundamental aspect of the aetiology of type 2 diabetes. Insulin resistance has been shown to be associated with atherosclerosis, dyslipidaemia, glucose intolerance, hyperuricaemia, hypertension and polycystic ovary syndrome. The mineral zinc plays a key role in the synthesis and action of insulin, both physiologically and in diabetes mellitus. Zinc seems to stimulate insulin action and insulin receptor tyrosine kinase activity.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-04-28 13:16:24 +0200" MODIFIED_BY="Bernd Richter">
<P>To assess the effects of zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-05-18 12:58:07 +0200" MODIFIED_BY="Gudrun Paletta">
<P>This review is an update of a previous Cochrane systematic review published in 2007. We searched the Cochrane Library (2015, Issue 3), MEDLINE, EMBASE, LILACS and the ICTRP trial register (from inception to March 2015). There were no language restrictions. We conducted citation searches and screened reference lists of included studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We included studies if they had a randomised or quasi-randomised design and if they investigated zinc supplementation compared with placebo or no intervention in adults with insulin resistance living in the community.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-05-14 16:33:36 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors selected relevant trials, assessed risk of bias and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We included three trials with a total of 128 participants in this review. The duration of zinc supplementation ranged between four and 12 weeks. Risk of bias was unclear for most studies regarding selection bias (random sequence generation, allocation concealment) and detection bias (blinding of outcome assessment). No study reported on our key outcome measures (incidence of type 2 diabetes mellitus, adverse events, health-related quality of life, all-cause mortality, diabetic complications, socioeconomic effects). Evaluation of insulin resistance as measured by the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) showed neutral effects when comparing zinc supplementation with control (two trials; 114 participants). There were neutral effects for trials comparing zinc supplementation with placebo for total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (2 studies, 70 participants). The one trial comparing zinc supplementation with exercise also showed neutral effects for total cholesterol, HDL and LDL cholesterol, and a mean difference in triglycerides of -30 mg/dL (95% confidence interval (CI) -49 to -10) in favour of zinc supplementation (53 participants). Various surrogate laboratory parameters were also analysed in the included trials.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>There is currently no evidence on which to base the use of zinc supplementation for the prevention of type 2 diabetes mellitus. Future trials should investigate patient-important outcome measures such as incidence of type 2 diabetes mellitus, health-related quality of life, diabetic complications, all-cause mortality and socioeconomic effects.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-05-19 16:45:51 +0200" MODIFIED_BY="Bernd Richter">
<BACKGROUND MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<CONDITION MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>This is an update of a Cochrane Review first published in the <I>Cochrane Library </I>in 2007 (<LINK REF="REF-Beletate-2007" TYPE="REFERENCE">Beletate 2007</LINK>), which included one study that did not provide evidence on patient-important outcome measures such as incidence of new-onset type 2 diabetes (<LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK>).</P>
<P>Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. A consequence of this is chronic hyperglycaemia (that is elevated levels of plasma glucose) with disturbances of carbohydrate, fat and protein metabolism. Long-term complications of diabetes mellitus include retinopathy, nephropathy and neuropathy. The risk of cardiovascular disease is increased (<LINK REF="REF-ADA-1999" TYPE="REFERENCE">ADA 1999</LINK>). There are two major forms of diabetes: type 1 diabetes (insulin-dependent diabetes mellitus (IDDM)) and type 2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM) (<LINK REF="REF-ADA-1999" TYPE="REFERENCE">ADA 1999</LINK>). Type 2 diabetes mellitus, the most prevalent form of the disease, is often asymptomatic and may remain undiagnosed for many years (<LINK REF="REF-ADA-1998" TYPE="REFERENCE">ADA 1998</LINK>). Type 2 diabetes may be seen in children and young adults. In type 2 diabetes the pancreatic islet cells are capable of compensating insulin resistance (see below) and producing larger quantities of insulin, at least at the beginning of the disease (<LINK REF="REF-Chausmer-1998" TYPE="REFERENCE">Chausmer 1998</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Prevalence and costs</HEADING>
<P>The worldwide prevalence of diabetes has been estimated to be around 347 million people (<LINK REF="REF-Danaei-2011" TYPE="REFERENCE">Danaei 2011</LINK>). In 2004, an estimated 3.4 million people died from consequences of high blood sugar (<LINK REF="REF-WHO-2009" TYPE="REFERENCE">WHO 2009</LINK>). The World Health Organization (WHO) projects that diabetes will be the 7th leading cause of death in 2030 (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>). Diabetes accounts for over EUR 77 billion (USD 98) in healthcare costs (<LINK REF="REF-Tracey-2003" TYPE="REFERENCE">Tracey 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">The risk of developing type 2 diabetes and insulin resistance</HEADING>
<P>The risk of developing type 2 diabetes increases with age, obesity and lack of physical activity. Insulin resistance is a fundamental aspect of the aetiology of type 2 diabetes (<LINK REF="REF-Kahn-2000" TYPE="REFERENCE">Kahn 2000</LINK>). The majority of people who develop type 2 diabetes are insulin resistant, a condition in which the pancreas produces insulin but the body's cells become increasingly resistant to the regular effects of insulin, which results in hyperglycaemia (<LINK REF="REF-Tracey-2003" TYPE="REFERENCE">Tracey 2003</LINK>). Insulin resistance has been shown to be associated with atherosclerosis (<LINK REF="REF-Howard-1996" TYPE="REFERENCE">Howard 1996</LINK>), dyslipidaemia (<LINK REF="REF-Moro-2003" TYPE="REFERENCE">Moro 2003</LINK>), glucose intolerance, hyperuricaemia, hypertension (<LINK REF="REF-Bonora-1998" TYPE="REFERENCE">Bonora 1998</LINK>), and polycystic ovary syndrome (<LINK REF="REF-Kahn-2000" TYPE="REFERENCE">Kahn 2000</LINK>).</P>
<P>Insulin resistance can be measured by using the glucose clamp technique (<LINK REF="REF-DeFronzo-1979" TYPE="REFERENCE">DeFronzo 1979</LINK>), which is considered the gold standard in the assessment of insulin sensitivity (<LINK REF="REF-Karelis-2004" TYPE="REFERENCE">Karelis 2004</LINK>). However, this method is laborious, expensive and inadequate for large-scale or epidemiological studies (<LINK REF="REF-Bonora-2000" TYPE="REFERENCE">Bonora 2000</LINK>). Matthews et al developed the Homeostasis Model Assessment (HOMA) method, which derives an estimate of insulin sensitivity by taking fasting plasma glucose and insulin concentrations into account. HOMA is supposed to evaluate insulin resistance and the function of ß-cells. Insulin resistance is calculated with the following formula: (fasting serum insulin (µU/ml) x fasting plasma glucose (mmol/L)/22.5 (<LINK REF="REF-Matthews-1985" TYPE="REFERENCE">Matthews 1985</LINK>).</P>
<P>Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are associated with insulin resistance. IFG and IGT refer to an intermediate metabolic stage between normal glucose homeostasis and diabetes. This stage includes individuals with fasting glucose levels equal to or greater than 110 mg/dL but lower than 126 mg/dL or after an orale glucose tolerance test with two-hour values equal to or greater than 140 mg/dL but lower than 200 mg/dL.</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Every single cell in the body needs zinc for structural and energy-producing functions. Zinc is an essential trigger for many biochemical reactions and also for protein production. Zinc plays an important role in cell division, growth and repair. It helps with wound healing and maintaining a normal sense of taste and smell. Zinc works as an immune booster and can be instrumental in fighting colds, flu and other infections. Zinc is a component of more than 200 enzymes, most of them involved in protein and DNA synthesis. Zinc has beneficial effects on sex and thyroid hormones. The human body does not produce zinc on its own, so it must be obtained from outside sources. The mineral zinc can be found in both animal and plant food sources, but the richest source of zinc comes from animal food.</P>
<P>The daily recommended dose of zinc is 12 mg for women and 15 mg for men. Studies suggest oral supplementation of zinc sulphate from 30 mg to 200 mg per day. The effect of supplementation with zinc was assessed in 10 patients with liver cirrhosis (<LINK REF="STD-Marchesini-1998" TYPE="STUDY">Marchesini 1998</LINK>). The patients presented with impaired glucose tolerance and zinc deficiency. Supplementation was approximately 136 mg zinc per day. The study showed that zinc supplementation produced a significant improvement in glucose disposal. The action of zinc seemed to be related to the increased activities of insulin independent glucose transporters (<LINK REF="STD-Marchesini-1998" TYPE="STUDY">Marchesini 1998</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects of the intervention</HEADING>
<P>Amounts of zinc of two or more grams per day can cause gastrointestinal irritation and vomiting (<LINK REF="STD-Marchesini-1998" TYPE="STUDY">Marchesini 1998</LINK>; <LINK REF="REF-Marreiro-2004" TYPE="REFERENCE">Marreiro 2004</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Zinc ions have an insulin-like effect. A particularly sensitive target of zinc ions is protein tyrosine phosphatase 1B, a key regulator of the phosphorylation state of the insulin receptor (<LINK REF="REF-Haase-2005" TYPE="REFERENCE">Haase 2005</LINK>). Several studies have investigated the role of zinc status in insulin secretion and metabolism. In vitro studies show that insulin may form a complex with zinc, improving the solubility of this hormone in the pancreatic &#946;-cells (<LINK REF="REF-Rossetti-1990" TYPE="REFERENCE">Rossetti 1990</LINK>). Moreover, the binding ability of insulin to its receptor may be increased (<LINK REF="REF-Rossetti-1990" TYPE="REFERENCE">Rossetti 1990</LINK>). Alterations in zinc concentration and distribution in tissues, as well as improvements in insulin sensitivity after supplementation with this element have been demonstrated (<LINK REF="STD-Marchesini-1998" TYPE="STUDY">Marchesini 1998</LINK>).<BR/>
</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Given the worldwide public health relevance of type 2 diabetes mellitus any intervention thought to be associated with only minor or no adverse effects should be investigated by means of a systematic review of the available evidence.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-04-15 14:14:43 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the effects of zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<SELECTION_CRITERIA MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<CRIT_STUDIES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We included randomised and quasi-randomised controlled clinical trials with a minimum duration of four weeks.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Non-diabetic adults (18 years or older) living in the community with insulin resistance.</P>
<SUBSECTION>
<HEADING LEVEL="4">Diagnostic criteria</HEADING>
<P>Insulin resistance had to be measured by the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) or the glucose clamp technique.<BR/>
</P>
<P>To be consistent with changes in the classification of and diagnostic criteria for diabetes mellitus over the years, the diagnosis should have been established using the standard criteria valid at the time of the trial commencing (for example <LINK REF="REF-ADA-1999" TYPE="REFERENCE">ADA 1999</LINK>; <LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>). Ideally, the diagnostic criteria should have been described. If necessary, we would have used the study authors' definition of diabetes mellitus. We planned to subject diagnostic criteria to a sensitivity analysis.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-05-18 11:43:26 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We planned to investigate the following comparisons of intervention versus control/comparator.</P>
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<UL>
<LI>Zinc</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparator</HEADING>
<UL>
<LI>Placebo.</LI>
<LI>No intervention.</LI>
<LI>Another dose of zinc.</LI>
</UL>
<P>Concomitant interventions had to be the same in the intervention and comparator groups to establish fair comparisons.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-05-18 11:43:34 +0200" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>Incidence of type 2 diabetes mellitus.</LI>
<LI>Adverse events.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>Insulin resistance.</LI>
<LI>Health-related quality of life.</LI>
<LI>All-cause mortality.</LI>
<LI>Diabetic complications.</LI>
<LI>Socioeconomic effects.</LI>
<LI>Lipid levels.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Method of outcome measurement</HEADING>
<UL>
<LI>Incidence of type 2 diabetes mellitus: new onset of type 2 diabetes mellitus as defined by standard diagnostic criteria (such as <LINK REF="REF-ADA-1997" TYPE="REFERENCE">ADA 1997</LINK>; <LINK REF="REF-ADA-1999" TYPE="REFERENCE">ADA 1999</LINK>; <LINK REF="REF-ADA-2003" TYPE="REFERENCE">ADA 2003</LINK>; <LINK REF="REF-WHO-1980" TYPE="REFERENCE">WHO 1980</LINK>; <LINK REF="REF-WHO-1985" TYPE="REFERENCE">WHO 1985</LINK>).</LI>
<LI>Adverse events: for example, diarrhoea, nausea, fatigue, gastrointestinal discomfort, anaemia.</LI>
<LI>Insulin resistance: estimated by the HOMA-IR or the glucose clamp technique.</LI>
<LI>Health-related quality of life: measured with a validated instrument such as the Quality of Well-Being Scale (QWB), Medical Outcomes Study 36-item Short-Form Health Survey (SF-36), EuroQol (EQ-5D) and specific instruments such as the Diabetes Care Profile (DCP) and the Diabetes Quality of Life Measure (DQOL).</LI>
<LI>All-cause mortality: defined as death from any cause.</LI>
<LI>Diabetic complications: defined as hypoglycaemia, diabetic ketoacidosis, hyperosmolar hyperglycaemic state, retinopathy, coronary heart disease, nephropathy, neuropathy, stroke and amputation.</LI>
<LI>Socioeconomic effects: such as consequences on income, wealth, education, occupation.</LI>
<LI>Lipid levels: as measured by total cholesterol, LDL and HDL cholesterol, triglycerides and leptin concentration.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Timing of outcome measurement</HEADING>
<P>We planned to collect data for all primary and secondary outcomes for any time of outcome measurement.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">'Summary of findings' table</HEADING>
<P>We present a 'Summary of findings' table reporting the following outcomes listed according to priority.</P>
<OL>
<LI>Incidence of type 2 diabetes mellitus.</LI>
<LI>Diabetic complications.</LI>
<LI>Adverse events.</LI>
<LI>Health-related quality of life.</LI>
<LI>All-cause mortality.</LI>
<LI>Socioeconomic effects.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-05-18 11:46:27 +0200" MODIFIED_BY="Gudrun Paletta">
<ELECTRONIC_SEARCHES MODIFIED="2015-05-18 11:46:00 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We searched the following sources from inception to the specified date without language restriction.</P>
<UL>
<LI>Cochrane Library (2015, Issue 3)</LI>
<UL>
<LI>Cochrane Database of Systematic Reviews (CDSR)</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Database of Abstracts of Reviews of Effects (DARE)</LI>
<LI>Health Technology Assessment (HTA) reports</LI>
</UL>
<LI>MEDLINE (until March 2015)</LI>
<LI>EMBASE (until March 2015)</LI>
<LI>LILACS (until March 2015)</LI>
<LI>International Clinical Trials Registry Platform (ICTRP) Search Portal (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>):</LI>
<UL>
<LI>Australian New Zealand Clinical Trials Registry (2 March 2015)</LI>
<LI>ClinicalTrials.gov (2 March 2015)</LI>
<LI>EU Clinical Trials Register (2 March 2015)</LI>
<LI>International Standard Randomised Controlled Trial Number (ISRCTN) (2 March 2015)</LI>
<LI>Brazilian Clinical Trials Registry (2 March 2015)</LI>
<LI>Chinese Clinical Trial Registry (2 March 2015)</LI>
<LI>Clinical Trials Registry - India (2 March 2015)</LI>
<LI>Clinical Research Information Service - Republic of Korea (2 March 2015)</LI>
<LI>Cuban Public Registry of Clinical Trials (2 March 2015)</LI>
<LI>German Clinical Trials Register (2 March 2015)</LI>
<LI>Iranian Registry of Clinical Trials (2 March 2015)</LI>
<LI>Japan Primary Registries Network (2 March 2015)</LI>
<LI>Pan African Clinical Trial Registry (2 March 2015)</LI>
<LI>Sri Lanka Clinical Trials Registry (2 March 2015)</LI>
<LI>The Netherlands National Trial Register (2 March 2015)</LI>
<LI>Thai Clinical Trials Register (2 March 2015)</LI>
</UL>
</UL>
<P>For detailed search strategies see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. We continuously applied a MEDLINE (via Ovid SP) email alert service to identify newly published studies (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405071131249944566887580626491&amp;format=REVMAN#APP-01">Appendix 1</A>). If we detected new studies for inclusion we would have evaluated these and incorporated findings in our review before submission of the final review draft (<LINK REF="REF-Beller-2013" TYPE="REFERENCE">Beller 2013</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-05-18 11:46:27 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, (systematic) reviews, meta-analyses and health technology assessment reports.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<STUDY_SELECTION MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Two review authors (LFOG, MSPO) independently scanned the title or abstract of every record retrieved. We retrieved full articles for further assessment if the information given suggested that the study: 1) included patients with insulin resistance, 2) compared a zinc intervention with placebo. Where differences in opinion existed, they were resolved by a third party (RED). If resolving disagreement was not possible, we planned to add the article to those 'awaiting classification' and contact the study authors for clarification. We present an adapted Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram to show the process of study selection (<LINK REF="REF-Liberati-2009" TYPE="REFERENCE">Liberati 2009</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>For studies that fulfilled the inclusion criteria, two review authors (LFOG, MSPO) independently abstracted relevant population and intervention characteristics, using standard data extraction templates as supplied by the Cochrane Metabolic and Endocrine Disorders (CMED) Group, with any disagreements to be resolved by discussion, or, if required, by a third review author (RED) (for details see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6;</LINK> <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>; <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>; <LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>; <LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>).</P>
<P>We planned to provide information including trial identifier about potentially relevant ongoing studies in the 'Characteristics of ongoing studies' table and in a joint appendix. We attempted to find the protocol for each included study and had planned to report primary, secondary and other outcomes in comparison with data in publications in a joint appendix 'Matrix of study endpoint (publications and trial documents)'.</P>
<P>We sent an email request to the authors of included studies to enquire whether they were willing to answer questions regarding their trials. <LINK REF="APP-11" TYPE="APPENDIX">Appendix 11</LINK> shows the results of this survey. Thereafter, we sought relevant missing information on the trial from the study authors of the article, if required.</P>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with duplicate and companion publications</HEADING>
<P>In the event of duplicate publications, companion documents or multiple reports of a primary study, we maximised the yield of information by collating all available data. In case of doubt the publication reporting the longest follow-up associated with our primary or secondary outcomes had priority.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Two review authors (LFOG, MSPO) assessed each trial independently. We resolved possible disagreement by consensus, or with consultation of a third review author in case of disagreement (RED). In cases of disagreement, we consulted the rest of the group and made a judgement based on consensus.</P>
<P>We used the 'Risk of bias' assessment toll of the Cochrane Collaboration (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>; <LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>) and evaluated the following bias criteria:</P>
<UL>
<LI>Random sequence generation (selection bias)</LI>
<LI>Allocation concealment (selection bias)</LI>
<LI>Blinding of participants and personnel (performance bias)</LI>
<LI>Blinding of outcome assessment (detection bias)</LI>
<LI>Incomplete outcome data (attrition bias)</LI>
<LI>Selective reporting (reporting bias)</LI>
<LI>Other potential sources of bias</LI>
</UL>
<P>We judged the above 'Risk of bias' criteria as 'low risk', 'high risk' or 'unclear risk' and evaluated individual bias items as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). We have presented a 'Risk of bias' graph and a 'Risk of bias' summary. We assessed the impact of individual bias domains on study results at endpoint and study levels.</P>
<P>We planned to assess outcome reporting bias by integrating the results of the appendix 'Matrix of study endpoints (publications and trial documents)' and the appendix 'Examination of outcome reporting bias' (<LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>). This analysis would have formed the basis of the judgement of selective reporting (reporting bias).</P>
<P>For blinding of participants and personnel (performance bias), detection bias (blinding of outcome assessors) and attrition bias (incomplete outcome data) we intended to evaluate risk of bias separately for subjective and objective outcomes (<LINK REF="REF-Hr_x00f3_bjartsson-2013" TYPE="REFERENCE">Hróbjartsson 2013</LINK>). We considered the implications of missing outcome data from individual participants.</P>
<P>We defined the following endpoints as subjective outcomes.</P>
<UL>
<LI>Adverse events</LI>
<LI>Health-related quality of life</LI>
</UL>
<P>We defined the following endpoints as objective outcomes.</P>
<UL>
<LI>Incidence of type 2 diabetes mellitus</LI>
<LI>Diabetic complications</LI>
<LI>All-cause mortality</LI>
<LI>Lipid levels</LI>
<LI>Socioeconomic effects</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-04-15 14:16:28 +0200" MODIFIED_BY="[Empty name]">
<P>We planned to express dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs). We planned to express continuous data as mean differences (MDs) with 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-04-15 14:16:28 +0200" MODIFIED_BY="[Empty name]">
<P>We planned to take into account the level at which randomisation occurred, such as cross-over trials, cluster-randomised trials and multiple observations for the same outcome.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We planned to obtain relevant missing data from authors, if feasible, and we evaluated important numerical data such as screened, eligible and randomised participants, as well as intention-to-treat (ITT), as-treated and per-protocol populations. We investigated attrition rates, for example drop-outs, losses to follow-up and withdrawals, and critically appraised issues of missing data and imputation methods (e.g. last observation carried forward (LOCF)).</P>
<P>Where standard deviations for outcomes were not reported, we planned to impute these values by assuming the standard deviation of the missing outcome to be the average of the standard deviations from those studies where this information was reported. We planned to investigate the impact of imputation on meta-analyses by means of sensitivity analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-04-15 14:16:27 +0200" MODIFIED_BY="[Empty name]">
<P>In the event of substantial clinical, methodological or statistical heterogeneity, we planned not to report study results as the pooled effect estimate in a meta-analysis.</P>
<P>We wanted to identify heterogeneity by visual inspection of the forest plots and by using a standard Chi² test with a significance level of &#945; = 0.1. In view of the low power of this test, we also planned to examine heterogeneity using the I² statistic, which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta-analysis (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), where an I² statistic of 75% or more indicates a considerable level of inconsistency (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
<P>Had we found heterogeneity, we would have attempted to determine potential reasons for it by examining individual study and subgroup characteristics.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We planned to use funnel plots to assess small study effects, if there were at least 10 studies for a particular outcome. There can be several explanations for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials) and publication bias. We planned therefore to interpret the results carefully (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Unless there was good evidence for homogeneous effects across studies we planned primarily to summarise low risk of bias data by means of a random-effects model (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>). We planned to interpret random-effects meta-analyses with due consideration of the whole distribution of effects, ideally by presenting a prediction interval (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). A prediction interval specifies a predicted range for the true treatment effect in an individual study (<LINK REF="REF-Riley-2011" TYPE="REFERENCE">Riley 2011</LINK>). In addition, we planned to perform statistical analyses according to the statistical guidelines referenced in the latest version of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Quality of evidence</HEADING>
<P>We wanted to present the overall quality of the evidence for each outcome according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, which takes into account issues not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias), but also to external validity such as directness of results<I>. </I>Two review authors (LFOG, MSPO) would have independently rated the quality of evidence for each outcome. We planned to present a summary of the evidence in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of the effect, in relative terms and as absolute differences, for each relevant comparison of alternative management strategies, numbers of participants, and studies addressing each important outcome and the rating of the overall confidence in effect estimates for each outcome. We created the 'Summary of findings' table based on the methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). We presented results for the outcomes as described in <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>. If meta-analysis was not possible, we planned to present the results in a narrative 'Summary of findings' table.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-05-14 14:28:02 +0200" MODIFIED_BY="[Empty name]">
<P>There were insufficient data to allow for any subgroup analyses. Should sufficient data in the future permit, we plan to carry out the following subgroup analyses and plan to investigate interaction.</P>
<UL>
<LI>Gender (female/male)</LI>
<LI>Age (depending on data but especially older versus younger participants)</LI>
<LI>Participants with or without comorbidities (for example, heart attack, stroke, peripheral vascular disease)</LI>
<LI>Duration of intervention</LI>
<LI>Different doses of zinc</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-05-18 12:13:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>There were insufficient data to allow for any sensitivity analyses to explore the influence of the following factors on effect size by restricting the analysis to:<BR/>
</P>
<UL>
<LI>Published studies.</LI>
<LI>Taking into account risk of bias, as specified in the '<LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK>' section.</LI>
<LI>Very long or large studies to establish how much they dominate the results.</LI>
<LI>Studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), or country.</LI>
</UL>
<P>We also planned to test the robustness of the results by repeating the analysis using different measures of effect size (RRs, ORs etc.) and different statistical models (fixed-effect and random-effects models).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-05-19 16:45:51 +0200" MODIFIED_BY="Bernd Richter">
<STUDY_DESCRIPTION MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>For a detailed description of studies, see the tables <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>In the first version of the review (2007) we evaluated 192 records. Following the assessment of the full articles, we considered only two publications for inclusion. We excluded one study (<LINK REF="STD-Marchesini-1998" TYPE="STUDY">Marchesini 1998</LINK>), and included one study that met our inclusion criteria (<LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK>). For this first update, our comprehensive literature searches identified 132 records; from these, we identified 14 full-text publications for further examination. We excluded the other studies on the basis of their titles or abstracts, because they did not meet the inclusion criteria or were not relevant to the question under study (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After screening the full text of the selected publications, two new studies (<LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK>; <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK>), and a further unpublished manuscript of <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK> met the inclusion criteria for this update. We excluded nine studies (<LINK REF="STD-Czernichow-2006" TYPE="STUDY">Czernichow 2006</LINK>; <LINK REF="STD-Czernichow-2009" TYPE="STUDY">Czernichow 2009</LINK>; <LINK REF="STD-Islam-2013" TYPE="STUDY">Islam 2013</LINK>; <LINK REF="STD-Kelishadi-2010" TYPE="STUDY">Kelishadi 2010</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>; <LINK REF="STD-Marreiro-2002" TYPE="STUDY">Marreiro 2002</LINK>; <LINK REF="STD-Marchesini-1998" TYPE="STUDY">Marchesini 1998</LINK>; <LINK REF="STD-Ramos-2007" TYPE="STUDY">Ramos 2007</LINK>; <LINK REF="STD-Stewart-2011" TYPE="STUDY">Stewart 2011</LINK>). One further study is an ongoing trial (<LINK REF="STD-Ranasinghe-2013" TYPE="STUDY">Ranasinghe 2013</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>In this first update we included two published
 
studies (<LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK>; <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK>), and a further manuscript (<LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK>), in addition to the original included study (<LINK REF="STD-Marreiro-2002" TYPE="STUDY">Marreiro 2002</LINK>), with a total of 128 randomised participants.</P>
<SUBSECTION>
<HEADING LEVEL="4">Overview of study populations</HEADING>
<P>The <LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK> study enrolled 14 obese men. The <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK> study included 56 normal glucose-tolerant obese women, while the <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK> study assessed 58 overweight or obese participants with a normal oral glucose tolerance test.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Study design</HEADING>
<P>All included studies claimed to be randomised controlled trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Settings</HEADING>
<P>Two of the included studies did not report the setting where the trials were conducted (<LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK>; <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK>). One study involved outpatients visiting hospital clinics (<LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>
<LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK> evaluated 14 men between 21 and 30 years old, while <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK> assessed 56 women aged 25 to 45 years. The mean age of participants in <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK> was 38 years.</P>
<P>
<LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK> recruited study participants with a prediabetic state and stable weight for at least three months before the beginning of the study. <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK> recruited glucose-tolerant obese women. <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK> recruited overweight or obese participants. The mean body mass index (BMI) at baseline ranged from 31 kg/m² in 
<LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK> to 36 kg/m² in <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK>. <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK> evaluated 58 first degree relatives of diabetic people with a normal oral glucose tolerance test and a BMI &gt; 25 kg/m²; the mean BMI was 29 kg/m².</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>In the <LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK> study participants received 100 mg zinc per day for four weeks (n = 7) or a matching placebo (n = 7). In the <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK> study treatment with zinc consisted of 30 mg per day for four weeks (n = 28) or a matching placebo (n = 28). In the <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK> study 28 participants received 50 mg zinc per day for 12 weeks and for 25 participants regular exercise and weight control were recommended.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>None of the included studies investigated the incidence of type 2 diabetes mellitus, adverse events, health-related quality of life, all-cause mortality, diabetic complications or socioeconomic effects.</P>
<P>In the <LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK> study the authors evaluated insulin sensitivity, leptin levels, biochemical profile and androgens. Outcome measures in the <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK> study were insulin resistance, anthropometric parameters, diet parameters, leptin levels, insulin levels, zinc levels, lipid metabolism and fasting plasma glucose. In the <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK> study adiponectin, fasting blood glucose, insulin, insulin resistance and lipid profile were assessed.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Nine studies are described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> (<LINK REF="STD-Czernichow-2006" TYPE="STUDY">Czernichow 2006</LINK>; <LINK REF="STD-Czernichow-2009" TYPE="STUDY">Czernichow 2009</LINK>; <LINK REF="STD-Islam-2013" TYPE="STUDY">Islam 2013</LINK>; <LINK REF="STD-Kelishadi-2010" TYPE="STUDY">Kelishadi 2010</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>; <LINK REF="STD-Marreiro-2002" TYPE="STUDY">Marreiro 2002</LINK>; <LINK REF="STD-Marchesini-1998" TYPE="STUDY">Marchesini 1998</LINK>; <LINK REF="STD-Ramos-2007" TYPE="STUDY">Ramos 2007</LINK>; <LINK REF="STD-Stewart-2011" TYPE="STUDY">Stewart 2011</LINK>). The main reason for exclusion was that the study was not a randomised controlled trial (RCT) or it was a RCT evaluating a combination of another oxidant and vitamins or included only children.</P>
<P>The <LINK REF="STD-Ranasinghe-2013" TYPE="STUDY">Ranasinghe 2013</LINK> study is described in detail under <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>. This is a RCT performed in Sri Lanka that evaluated participants in a prediabetic stage. The anticipated end of study was the end of June 2012. Participants received 20 mg zinc per day or a matching placebo for a period of 12 months. The objectives of this study were as follows: "The study aims to evaluate the effects of zinc supplementation on the progression of disease in patients with pre-diabetes from Sri Lanka and determine the metabolic effects of zinc supplementation on glycemic control. Furthermore, we aim to evaluate the effects of zinc supplementation on appetite and body weight in patients with pre-diabetes" (<LINK REF="STD-Ranasinghe-2013" TYPE="STUDY">Ranasinghe 2013</LINK>). None of our review's primary or secondary outcome measures were planned to be analysed.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-05-19 16:45:51 +0200" MODIFIED_BY="Bernd Richter">
<P>For details on the risk of bias of the included studies see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. For an overview of review authors' judgements about each risk of bias item for individual studies and across all studies see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2015-05-19 16:44:23 +0200" MODIFIED_BY="Bernd Richter">
<P>All included studies had an unclear risk of selection bias with the exception of <LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK> that used opaque and sealed envelopes in a simple randomisation process. </P>
</ALLOCATION>
<BLINDING MODIFIED="2015-05-19 16:45:51 +0200" MODIFIED_BY="Bernd Richter">
<P>Two studies were double-blinded for both investigators and participants resulting in a low risk of performance bias (<LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK>; <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK>). Two of the included studies did not report on blinding of outcome assessors (<LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK>; <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK>) and were ranked as unclear risk of bias for this domain. However, blinding of outcome assessors in <LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK> was done for both objective and subjective outcomes resulting in a low risk of detection bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-05-19 16:04:32 +0200" MODIFIED_BY="[Empty name]">
<P>All participants in the <LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK> and <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK> studies completed the trial. In the <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK> study 53 of 58 participants completed the study. Altogether we ranked attrition bias as low risk for all studies.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-05-18 12:34:25 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We noted no evidence of selective reporting in any of the included studies.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-05-18 12:34:29 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We noted no evidence of other potential sources of bias in any of the included studies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<SUBSECTION>
<HEADING LEVEL="3">Zinc supplementation versus placebo or no intervention</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Incidence of type 2 diabetes mellitus</HEADING>
<P>No study reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No study reported this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Insulin resistance</HEADING>
<P>
<LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK> reported neutral effects for the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), showing a mean difference (MD) of -0.10 (95% confidence interval (CI) -1.28 to 1.08), P = 0.87; 56 participants; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> when comparing zinc supplementation with placebo. <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK> reported a MD in the HOMA-IR of -0.27 (95% CI -1.02 to 0.48), P = 0.48; 58 participants; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> for zinc supplementation versus exercise.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Health-related quality of life</HEADING>
<P>No study reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality</HEADING>
<P>No study reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Diabetic complications</HEADING>
<P>No study reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Socioeconomic effects</HEADING>
<P>No study reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipid levels</HEADING>
<P>All included studies reported on this outcome (<LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK>; <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK>; <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK>). There were neutral effects for studies comparing zinc supplementation with placebo for total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (<LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK>; <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK>) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The one study comparing zinc supplementation with exercise, <LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK>, also showed neutral effects for total, HDL andLDL cholesterol, and a MD in triglycerides of -30 mg/dL (95% CI -49 to -10) in favour of zinc supplementation (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Additional parameters evaluated in the included studies</HEADING>
<P>One study reported on body mass index, body perimeter, body constitution, skinfold thickness below the scapula, skinfold thickness above the hip bone, skinfold thickness of the upper arm, body mass index, waist, waist-hip ratio, energy and nutrient intake, and percentage of fat as obtained by bioimpedance (<LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK>). <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK> also measured zinc concentrations in plasma, erythrocytes and urine.</P>
<P>One study reported on insulin, glucose, creatinine, uric acid, leptin, testosterone and sex hormone binding globulin (<LINK REF="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TYPE="STUDY">Gómez-García 2006</LINK>).</P>
<P>One study measured adiponectin, insulin and fasting blood sugar (FBS) (<LINK REF="STD-Soheilykhah-2012" TYPE="STUDY">Soheilykhah 2012</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<SUMMARY_OF_RESULTS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>This systematic review offers up-to-date but very limited evidence supported by only three small randomised controlled trials regarding the effects of zinc supplementation for the prevention of type 2 diabetes mellitus. The relationship between obesity and insulin resistance is seen across all ethnic groups and is evident across the full range of body weights. Insulin resistance is thought to be a major feature of type 2 diabetes, particularly since high basal plasma insulin concentrations are often found in obese type 2 diabetic people. Unfortunately, none of our patient-important outcome measures were reported in the included studies. Only parameters of insulin resistance and lipid levels were reported, showing neutral effects.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>None of the included studies investigated our predefined outcome measure, therefore the body of evidence is very limited. <LINK REF="STD-Marreiro-2006" TYPE="STUDY">Marreiro 2006</LINK> suggested future trials with higher doses of zinc and longer follow-up intervals, since four weeks and a dose of 30 mg of zinc are not sufficient to assess a long-term process like the development of glucose intolerance and diabetes.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-05-18 12:37:31 +0200" MODIFIED_BY="Gudrun Paletta">
<P>The methodological quality of the included studies could not be judged according to the GRADE approach because none of our key endpoints were evaluated in the included studies.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Despite our thorough search in various databases we might have overlooked trials, especially with regard to the grey literature. However, we contacted the authors of the included studies to ask whether they had done another trial dealing with zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>The results of our review reflect those of the previous version of this review (<LINK REF="REF-Beletate-2007" TYPE="REFERENCE">Beletate 2007</LINK>). Another systematic review of randomised controlled trials evaluated the effects of zinc supplementation on biomarkers of glycaemic control included type 1 and type 2 diabetic participants, participants with metabolic syndrome, participants with obesity and healthy persons (<LINK REF="REF-Capdor-2013" TYPE="REFERENCE">Capdor 2013</LINK>). When comparing participants with metabolic conditions to healthy volunteers the study authors showed that zinc supplementation produced a greater reduction in glucose concentrations.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<IMPLICATIONS_PRACTICE MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>There is currently no evidence on which to base the use of zinc supplementation for the prevention of type 2 diabetes mellitus.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>There are only three included studies evaluating the effects of zinc supplementation for the prevention of type 2 diabetes mellitus. Future randomised controlled clinical trials should have standardised outcome measures, such as incidence of type 2 diabetes mellitus, insulin resistance, diabetic complications, health-related quality of life, all-cause mortality and socioeconomic outcome measures.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-05-19 16:53:06 +0200" MODIFIED_BY="Bernd Richter">
<P>The authors would like to thank Regis Bruni Andriolo for his useful advice in the development of the original review. We also would like to thank Karla Bergerhoff and Maria-Inti Metzendorf for the searches done for this review update. We also are thankful for Dr. Esperanza Martínez-Abundis and Dr. Gómez-García who provided us with further information and details of their publications.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-04-23 19:32:04 +0200" MODIFIED_BY="[Empty name]">
<P>RED: none known.</P>
<P>LFOG: none known.</P>
<P>MSPO: none known.</P>
<P>NSPM: none known.</P>
<P>LGB: none known.</P>
<P>ECJ: none known.</P>
<P>PNJ: none known.</P>
<P>VB: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-05-19 15:49:57 +0200" MODIFIED_BY="[Empty name]">
<P>Regina El Dib (RED): co-ordinating the review, data management, interpretation of data, writing the review, securing funding for the review, guarantor for the review, responsible for reading and checking the review before submission.</P>
<P>Luis Felipe Orsi Gameiro (LFOG): undertaking manual searches, screening search results, organising retrieval of publications, screening retrieved publications against inclusion criteria, appraising quality of publications, abstracting data from publications, obtaining and screening data on unpublished studies, data management for the review, entering data into Review Manager, double entry of data.</P>
<P>Matheus SP Ogata (MSPO): providing additional data about publications, abstracting data from publications, obtaining and screening data on unpublished studies, entering data into Review Manager, double entry of data.</P>
<P>Norma SP Módolo (NSPM): responsible for reading and checking the review before submission.</P>
<P>Leandro G Braz (LGB): responsible for reading and checking the review before submission.</P>
<P>Eliane C Jorge: responsible for reading and checking the review before submission.</P>
<P>Paulo do Nascimento Junior (PNJ): responsible for reading and checking the review before submission.</P>
<P>Vânia Beletate (VB): conceiving the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>This review is an update of the previous Cochrane systematic review, which included one RCT (<LINK REF="REF-Beletate-2007" TYPE="REFERENCE">Beletate 2007</LINK>).</P>
<P>The previous author Álvaro Atallah decided not to participate in the update of the review. For this update the following new authors contributed: Luis Felipe Orsi Gameiro, Matheus Senna Pereira Ogata, Norma Sueli Pinheiro Modolo, Leandro Gobbo Braz, Eliane C Jorge and Paulo do Nascimento Junior.</P>
<P>We updated the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section (added the 'Summary of findings' table and the new 'Risk of bias' assessment). We changed adverse events from a secondary to a primary outcome measure.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<STUDIES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<INCLUDED_STUDIES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<STUDY DATA_SOURCE="PUB" ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Gómez-García 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gómez-García A, Hernández-Salazar E, González-Ortiz M, Martínez-Abundis E</AU>
<TI>Effect of oral zinc administration on insulin sensitivity, leptin and androgens in obese males</TI>
<SO>Revista Medica de Chile</SO>
<YR>2006</YR>
<VL>134</VL>
<PG>279-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marreiro-2006" MODIFIED="2015-04-16 20:49:42 +0200" MODIFIED_BY="[Empty name]" NAME="Marreiro 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-04-16 20:49:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marreiro DN, Geloneze B, Tambascia M, Lerário A, Halpern A, Cozzolino SM</AU>
<TI>Effect of zinc supplementation on serum leptin levels and insulin resistance of obese women</TI>
<SO>Biological Trace Element Research</SO>
<YR>2006</YR>
<VL>112</VL>
<PG>109-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-30 21:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Marreiro DN</AU>
<TI>The effect of zinc supplementation in insulin resistance in obesity women.</TI>
<TO>Efeito da suplementação com zinco na resistência à insulina em mulheres obesas</TO>
<SO>Tese de doutorado - Faculdade de Ciências Farmacêuticas - USP, São Paulo, Brazil</SO>
<YR>2002</YR>
<PG>109p.</PG>
<CY>São Paulo</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soheilykhah-2012" MODIFIED="2014-09-30 21:05:48 +0200" MODIFIED_BY="[Empty name]" NAME="Soheilykhah 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-09-30 21:05:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soheilykhah S, Dehestani M, Mohammadi S, Afkhami-Ardeni M, Eghbali S, Dehghan F</AU>
<TI>The effect of zinc supplementation on serum adiponectin concentration and insulin resistance in first degree relatives of diabetic patients</TI>
<SO>Iranian Journal of Diabetes and Obesity</SO>
<YR>2012</YR>
<VL>4</VL>
<NO>2</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<STUDY DATA_SOURCE="PUB" ID="STD-Czernichow-2006" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Czernichow 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czernichow S, Couthouis A, Bertrais S, Vergnaud AC, Dauchet L, Galan P, et al</AU>
<TI>Antioxidant supplementation does not affect fasting plasma glucose in the supplementation with antioxidant vitamins and minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>84</VL>
<PG>395-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-03-04 23:52:51 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czernichow-2009" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Czernichow 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czernichow S, Vergnaud AC, Galan P, Arnaud J, Favier A, Faure H, et al</AU>
<TI>Effects of long-term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic syndrome in adults</TI>
<SO>Journal of Clinical Nutrition</SO>
<YR>2009</YR>
<VL>90</VL>
<PG>329-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Islam-2013" MODIFIED="2015-05-14 15:15:05 +0200" MODIFIED_BY="[Empty name]" NAME="Islam 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-05-14 15:15:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Islam R, Arslan I, Attia J, McEvoy M, McElduff P, Basher A, et al</AU>
<TI>Is serum zinc level associated with prediabetes and diabetes?: A cross-sectional study from Bangladesh</TI>
<SO>PloS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>4</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelishadi-2010" MODIFIED="2015-04-08 17:59:44 +0200" MODIFIED_BY="Bernd Richter" NAME="Kelishadi 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-04-08 17:59:44 +0200" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelishadi R, Hashemipour M, Adeli K, Tavakoli N, Movahedian-Attar A, Shapouri J, et al</AU>
<TI>Effect of zinc supplementation on markers of insulin resistance, oxidative stress, and inflammation among prepubescent children with metabolic syndrome</TI>
<SO>Metabolic Syndrome and Related Disorders</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>6</NO>
<PG>1-6</PG>
<IDENTIFIERS MODIFIED="2014-03-05 20:30:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-05 20:30:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1089/met.2010.0020"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2012" MODIFIED="2014-03-11 17:32:24 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-11 17:32:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim J, Lee S</AU>
<TI>Effect of zinc supplementation on insulin resistance and metabolic risk factors in obese Korean women</TI>
<SO>Nutrition Research and Practice</SO>
<YR>2012</YR>
<VL>6</VL>
<NO>3</NO>
<PG>221-5</PG>
<IDENTIFIERS MODIFIED="2014-03-05 21:02:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-05 21:02:24 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="http://dx.doi.org/10.4162/nrp.2012.6.3.221"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marchesini-1998" NAME="Marchesini 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marchesini G, Bugianesi E, Ronchi M, Flamia R, Thomaseth K, Pacini G</AU>
<TI>Zinc supplementation improves glucose disposal in patients with cirrhosis</TI>
<SO>Metabolism Baltimore</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>792-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marreiro-2002" MODIFIED="2015-04-08 18:00:23 +0200" MODIFIED_BY="Bernd Richter" NAME="Marreiro 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-04-08 18:00:23 +0200" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marreiro DN, Fisberg M, Cozzolino SM</AU>
<TI>Zinc nutritional status in obese children and adolescents</TI>
<SO>Biological Trace Element Research</SO>
<YR>2002</YR>
<VL>86</VL>
<NO>2</NO>
<PG>107-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramos-2007" MODIFIED="2015-05-14 15:15:46 +0200" MODIFIED_BY="[Empty name]" NAME="Ramos 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-14 15:15:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramos RI, Atalah E, Urteaga C, Castañeda R, Orozco M, Avila L, et al</AU>
<TI>Effect of the consumption of a food supplement on plasma zinc concentrations of free-living Chilean elderly adults</TI>
<SO>Revista Medica de Chile</SO>
<YR>2007</YR>
<VL>135</VL>
<PG>1015-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stewart-2011" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Stewart 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart C, Christian P, Schulze K, Arguello M, LeClerq S, Khatry S, et al</AU>
<TI>Low maternal vitamin B-12 status is associated with offspring insulin resistance regardless of antenatal micronutrient supplementation in rural Nepal</TI>
<SO>Journal of Nutrition</SO>
<YR>2011</YR>
<VL>141</VL>
<PG>1912-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2015-04-10 13:07:55 +0200" MODIFIED_BY="Bernd Richter">
<STUDY DATA_SOURCE="PUB" ID="STD-Ranasinghe-2013" MODIFIED="2015-04-10 13:07:55 +0200" MODIFIED_BY="Bernd Richter" NAME="Ranasinghe 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-04-10 13:07:55 +0200" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranansinghe P, Jayawardena R, Pigera A, Katulanda P, Constantine G, Galappaththy P</AU>
<TI>Zinc supplementation in pre-diabetes: study protocol for a randomized controlled trial</TI>
<SO>Trials</SO>
<YR>2013</YR>
<VL>14</VL>
<NO>52</NO>
<PG>2-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1186/1745-6215-14-52"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-09-16 16:02:34 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1186/1745-6215-14-52"/>
<IDENTIFIER MODIFIED="2014-09-16 16:02:06 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SLCTR/2012/010"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<ADDITIONAL_REFERENCES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<REFERENCE ID="REF-ADA-1997" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="ADA 1997" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Report on the expert committee on the diagnosis and classification of diabetes mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>Suppl 1</NO>
<PG>S5&#8211;20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-1998" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="ADA 1998" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Screening for type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>22</VL>
<NO>Suppl 1</NO>
<PG>S20-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-1999" MODIFIED="2013-10-02 11:17:44 +0200" MODIFIED_BY="[Empty name]" NAME="ADA 1999" TYPE="JOURNAL_ARTICLE">
<AU>The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</AU>
<TI>Report of the expert committee on the diagnosis and classification of diabetes mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>Suppl 1</NO>
<PG>S5-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-2003" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="ADA 2003" TYPE="JOURNAL_ARTICLE">
<AU>The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</AU>
<TI>Report of the expert committee on the diagnosis and classification of diabetes mellitus</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>Suppl 1</NO>
<PG>S5&#8211;20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beller-2013" MODIFIED="2013-10-02 11:18:17 +0200" MODIFIED_BY="G P" NAME="Beller 2013" TYPE="JOURNAL_ARTICLE">
<AU>Beller EM, Chen JK, Wang UL, Glasziou PP</AU>
<TI>Are systematic reviews up-to-date at the time of publication?</TI>
<SO>Systematic Reviews</SO>
<YR>2013</YR>
<VL>2</VL>
<NO>1</NO>
<PG>36</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="2046-4053" TYPE="OTHER" VALUE="(Electronic)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bonora-1998" MODIFIED="2015-04-08 18:01:32 +0200" MODIFIED_BY="Bernd Richter" NAME="Bonora 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bonora E, Kiechi E, Willeit J, Oberhollenzer F, Egger G, Targher G, et al</AU>
<TI>Prevalence of insulin resistance in metabolic disorders</TI>
<SO>Diabetes</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>1643-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonora-2000" MODIFIED="2015-04-08 18:01:53 +0200" MODIFIED_BY="Bernd Richter" NAME="Bonora 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al</AU>
<TI>Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity</TI>
<SO>Diabetes Care</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>1</NO>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Capdor-2013" MODIFIED="2015-04-08 18:02:17 +0200" MODIFIED_BY="Bernd Richter" NAME="Capdor 2013" TYPE="JOURNAL_ARTICLE">
<AU>Capdor J, Foster M, Petocz P, Samman S</AU>
<TI>Zinc and glycemic control: a meta-analysis of randomised placebo controlled supplementation trials in humans</TI>
<SO>Journal of Trace Elements in Medicine and Biology</SO>
<YR>2013</YR>
<VL>27</VL>
<PG>137-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chausmer-1998" MODIFIED="2014-10-21 10:28:06 +0200" MODIFIED_BY="[Empty name]" NAME="Chausmer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Chausmer AB</AU>
<TI>Zinc, insulin and diabetes</TI>
<SO>Journal of the American College of Nutrition</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>2</NO>
<PG>109-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Danaei-2011" MODIFIED="2014-04-21 22:15:19 +0200" MODIFIED_BY="[Empty name]" NAME="Danaei 2011" TYPE="JOURNAL_ARTICLE">
<AU>Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al</AU>
<TI>National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>378</VL>
<PG>31-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeFronzo-1979" MODIFIED="2015-05-18 15:15:51 +0200" MODIFIED_BY="Gudrun Paletta" NAME="DeFronzo 1979" TYPE="JOURNAL_ARTICLE">
<AU>DeFronzo RA, Tobin JD, Andres R</AU>
<TI>Glucose Clamp technique: a method for quantifying insulin secretion and resistance</TI>
<SO>American Journal of Physiology</SO>
<YR>1979</YR>
<VL>237</VL>
<PG>E214-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haase-2005" NAME="Haase 2005" TYPE="JOURNAL_ARTICLE">
<AU>Haase H, Maret W</AU>
<TI>Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants</TI>
<SO>Biometals</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>4</NO>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2013-10-02 08:25:25 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-05-18 15:15:51 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>555-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2013-10-02 08:25:25 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Spiegelhalter DJ</AU>
<TI>A re-evaluation of random-effects meta-analysis</TI>
<SO>Journal of the Royal Statistical Society. Series A, (Statistics in Society)</SO>
<YR>2009</YR>
<VL>172</VL>
<NO>1</NO>
<PG>137-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2015-05-14 15:19:16 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2013-10-02 08:27:07 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al</AU>
<TI>The Cochrane Collaboration's tool for assessing risk of bias in randomised trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d5928</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard-1996" MODIFIED="2015-05-18 15:15:51 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Howard 1996" TYPE="JOURNAL_ARTICLE">
<AU>Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, et al</AU>
<TI>Insulin sensitivity and atherosclerosis: the Insulin Resistance Atherosclerosis Study (IRAS) Investigators</TI>
<SO>Circulation</SO>
<YR>1996</YR>
<VL>93</VL>
<PG>1809-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hr_x00f3_bjartsson-2013" MODIFIED="2013-10-02 08:25:25 +0200" MODIFIED_BY="[Empty name]" NAME="Hróbjartsson 2013" TYPE="JOURNAL_ARTICLE">
<AU>Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al</AU>
<TI>Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2013</YR>
<VL>185</VL>
<NO>4</NO>
<PG>E201-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kahn-2000" MODIFIED="2014-10-21 10:27:10 +0200" MODIFIED_BY="[Empty name]" NAME="Kahn 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kahn BB, Flier JS</AU>
<TI>Obesity and insulin resistance</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>2000</YR>
<VL>106</VL>
<NO>4</NO>
<PG>473-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karelis-2004" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Karelis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Karelis AD, Henry JF, Malita F, St-Pierre DH, Vigneault I, Poehlman ET, et al</AU>
<TI>Comparison of insulin sensitivity values using the hyperinsulinemic euglycemic clamp: 2 vs 3 hours</TI>
<SO>Diabetes &amp; Metabolism</SO>
<YR>2004</YR>
<VL>30</VL>
<PG>413-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirkham-2010" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Kirkham 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al</AU>
<TI>The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c365</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1136/bmj.c365"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2009" MODIFIED="2014-04-28 14:56:51 +0200" MODIFIED_BY="G P" NAME="Liberati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al</AU>
<TI>The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration</TI>
<SO>PLoS Medicine</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>7</NO>
<PG>1-28</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1371/journal.pmed.1000100"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marreiro-2004" MODIFIED="2014-10-21 10:34:51 +0200" MODIFIED_BY="[Empty name]" NAME="Marreiro 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marreiro DN, Geloneze B, Tambascia MA, Lerário AC, Halpern A, Cozzolino SMF</AU>
<TI>Participation of zinc in insulin resistance</TI>
<TO>Participaçäo do zinco na resistência à insulina</TO>
<SO>Arquivos brasileiros de endocrinologia e metabologia</SO>
<YR>2004</YR>
<VL>48</VL>
<NO>2</NO>
<PG>234-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matthews-1985" MODIFIED="2014-10-21 10:38:23 +0200" MODIFIED_BY="[Empty name]" NAME="Matthews 1985" TYPE="JOURNAL_ARTICLE">
<AU>Matthews DR, Hosker JP, Rudenski BA, Naylor BA, Treacher DF, Turner RC</AU>
<TI>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</TI>
<SO>Diabetologia</SO>
<YR>1985</YR>
<VL>28</VL>
<PG>412-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moro-2003" MODIFIED="2014-10-21 10:39:03 +0200" MODIFIED_BY="[Empty name]" NAME="Moro 2003" TYPE="JOURNAL_ARTICLE">
<AU>Moro E, Gallina P, Pais M, Cazzolato G, Alessandrini P, Bittolo-Bon G</AU>
<TI>Hypertriglyceridemia is associated with increased insulin resistance in subjects assessed with the 1999 World Health Organization criteria for the classification of diabetes</TI>
<SO>Metabolism: Clinical and Experimental</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>5</NO>
<PG>616-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riley-2011" MODIFIED="2013-10-02 08:25:25 +0200" MODIFIED_BY="[Empty name]" NAME="Riley 2011" TYPE="JOURNAL_ARTICLE">
<AU>Riley RD, Higgins JP, Deeks JJ</AU>
<TI>Interpretation of random effects meta-analyses</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d549</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossetti-1990" NAME="Rossetti 1990" TYPE="JOURNAL_ARTICLE">
<AU>Rossetti L, Giaccari A, Klein-Robbenhaar E, Vogel LR</AU>
<TI>Insulinomimetic properties of trace elements and characterization of their in vivo mode of action</TI>
<SO>Diabetes</SO>
<YR>1990</YR>
<VL>39</VL>
<PG>1243-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Sterne 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al</AU>
<TI>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d4002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tracey-2003" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Tracey 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tracey L, Mclaughlin MD, Gerald M, Reaven MD</AU>
<TI>Beyond type 2 diabetes: The need for a clinically useful way to identify insulin resistance</TI>
<SO>American Journal of Medicine</SO>
<YR>2003</YR>
<VL>114</VL>
<PG>501-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1980" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="WHO 1980" TYPE="OTHER">
<AU>WHO Expert Committee on Diabetes Mellitus. Second Report</AU>
<TI>Technical Report Series 646</TI>
<SO>Geneva: World Health Organization</SO>
<YR>1980</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1985" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="WHO 1985" TYPE="OTHER">
<AU>WHO Expert Committee on Diabetes Mellitus</AU>
<TI>Technical Report Series 727</TI>
<SO>Geneva: World Health Organization</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1999" MODIFIED="2014-10-21 10:40:28 +0200" MODIFIED_BY="[Empty name]" NAME="WHO 1999" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus</TI>
<SO>Geneva: World Health Organization</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2009" MODIFIED="2015-05-14 15:25:07 +0200" MODIFIED_BY="[Empty name]" NAME="WHO 2009" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Global health risks. Mortality and burden of disease attributable to selected major risks</TI>
<SO>World Health Organization</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2011" MODIFIED="2015-05-14 15:25:19 +0200" MODIFIED_BY="[Empty name]" NAME="WHO 2011" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Global status report on noncommunicable diseases 2010</TI>
<SO>World Health Organization</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-2006" MODIFIED="2015-04-08 18:06:57 +0200" MODIFIED_BY="Bernd Richter" NAME="Wong 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wong SSL, Wilczynski NL, Haynes RB</AU>
<TI>Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>1</NO>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-05-08 15:59:37 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Beletate-2007" MODIFIED="2014-05-08 15:59:37 +0200" MODIFIED_BY="[Empty name]" NAME="Beletate 2007" TYPE="COCHRANE_REVIEW">
<AU>Beletate V, El Dib RP, Atallah AN</AU>
<TI>Zinc supplementation for the prevention of type 2 diabetes mellitus</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-04-18 17:36:53 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-18 17:36:53 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005525.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-05-19 16:49:22 +0200" MODIFIED_BY="Bernd Richter">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-05-19 16:49:22 +0200" MODIFIED_BY="Bernd Richter" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Study details" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Publication details" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Stated aim for study">
<INCLUDED_CHAR MODIFIED="2015-05-19 16:48:38 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006">
<CHAR_METHODS MODIFIED="2015-05-19 16:47:54 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>Design:</B> single-centre, randomised, triple-blind, placebo-controlled clinical trial (information provided by contact with author)</P>
<P>
<B>Setting:</B> Medical Research Unit in Clinical Epidemiology, Hospital of Specialties, West National Medical Center of the Mexican Institute of Social Security, Guadalajara, Mexico (information provided by contact with author)</P>
<P>
<B>Sample size: </B>the sample size was calculated with a formula for clinical trials with a confidence level of 95% power to test a standard deviation of 80% of the euglycaemic hyperinsulinaemic clamp 0.8 mg/Kg/min and an expected difference of at least twice the standard deviation, so that a score of 6 participants per group was obtained; due to the possibility of loss during the follow-up, 7 participants were included per group</P>
<P>
<B>Intention-to-treat analysis: "</B>We contemplated an intention-to-treat analysis, however, no subject had to be excluded from the study" [information retrieved by contact with the study authors]</P>
<P>
<B>Follow-up: </B>1 month</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-19 16:48:04 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>N = 14</B>
</P>
<P>
<B>Inclusion criteria:</B> participants included 14 obese men aged between 21 to 30 years old (body mass index (BMI) 27 kg/m²). Also, these volunteers had first degree relatives with diabetes mellitus type 2 and sustained a stable body weight for at least 3 months before the beginning of the study</P>
<P>
<B>Exclusion criteria: </B>Quote from contact with the study author by email: "The exclusion criterion was the intake of any medication with effect on the metabolism of carbohydrates, lipids, zinc, or insulin during the intervention. However, no subject had to be excluded from the study"<BR/>
</P>
<P>
<B>Diagnostic criteria:</B> insulin sensitivity measured by the glucose clamp method</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-19 16:48:38 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>Number of study centres: </B>1</P>
<P>
<B>Treatment before study:</B> Quote from contact with the study author by email: "The volunteers did not ingest any treatment at least in the month preceding the study"</P>
<P>
<B>Intervention and control groups: </B>100 mg/day of zinc sulfate orally (n = 7) versus placebo (n = 7)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-14 14:54:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes reported in abstract of publication:</B> insulin sensitivity, leptin levels, biochemical profile and androgens</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-05-18 12:42:21 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Run-in period: </B>1 month</P>
<P>
<B>Study terminated before regular end (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication:</B> Spanish</P>
<P>
<B>Commercial funding/non-commercial funding/other funding: </B>Fondo de Fomento a la Investigacion del Insituto Mexicano del Seguro Social - Fund of Scientific Support of The Mexican Institute of Social Security</P>
<P>
<B>Publication status: </B>journal article</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-05-18 12:39:20 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To assess the effects of zinc sulfate on insulin sensitivity, leptin and androgens in obese individuals"</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-05-18 12:42:02 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We contacted the author on 16 April 2015 to request information about risk of bias. The author kindly replied with all the information requested on 18 April 2015</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Marreiro-2006">
<CHAR_METHODS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Design:</B> randomised, double-blind, placebo-controlled study</P>
<P>
<B>Setting: </B>outpatient (hospital clinics)</P>
<P>
<B>Intention-to-treat analysis: </B>not reported</P>
<P>
<B>Follow-up: </B>4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>N = 56</B>
</P>
<P>
<B>Inclusion criteria:</B> age ranging between 25 and 45 years, obesity class I and II, absence of vitamin and mineral supplementation and/or use other medication that could interfere with zinc and insulin action, nonsmokers, absence of hormone replacement therapy and/or use of oral contraceptives, and without diseases that could interfere with the nutritional status regarding zinc and insulin resistance, such as type 2 diabetes, polycystic ovary syndrome, hypertension or chronic kidney failure</P>
<P>
<B>Exclusion criteria:</B> not reported<BR/>
</P>
<P>
<B>Diagnostic criteria: </B>determination of insulin resistance was performed using the Homeostasis Model Assessment (HOMA) model as proposed by Matthews and co-workers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-18 12:41:30 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres:</B> 1</P>
<P>
<B>Treatment before study:</B> none</P>
<P>
<B>Intervention and control groups: </B>participants received oral zinc consisted 30 mg per day for 4 weeks (n = 28) or placebo (n = 28)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-14 14:54:51 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes reported in abstract of publication:</B> BMI, fasting glucose, zinc concentration in plasma, insulin, HOMA-IR, and leptin</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-05-18 12:41:20 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Run-in period: 4</B> weeks</P>
<P>
<B>Study terminated before regular end (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2015-05-18 12:40:10 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication:</B> English</P>
<P>
<B>Commercial funding/non-commercial funding/other funding: </B>not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-04-15 16:37:12 +0200" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "This study was conducted with the purpose to evaluating the effect of zinc supplementation on leptin levels in obese women"</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>There is a further unpublished manuscript reporting complementary outcomes</P>
<P>We contacted the author on 16 April 2015 to request information about risk of bias. We are awaiting a reply</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Soheilykhah-2012">
<CHAR_METHODS MODIFIED="2015-05-18 12:41:00 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Design: </B>randomised clinical trial</P>
<P>
<B>Setting: </B>not reported</P>
<P>
<B>Intention-to-treat analysis: </B>not reported</P>
<P>
<B>Follow-up: </B>12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-18 12:41:05 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>N = 53</B>
</P>
<P>
<B>Inclusion criteria:</B> more than 25 years and BMI more than 25 kg/m² with normal 75 g oral glucose tolerance test</P>
<P>
<B>Exclusion criteria:</B> first degree relatives of participants who consumed vitamin D or magnesium supplementation in the past 6 months<BR/>
</P>
<P>
<B>Diagnostic criteria:</B> prediabetic participants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-18 12:40:57 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres: </B>1</P>
<P>
<B>Treatment before study:</B> none reported</P>
<P>
<B>Intervention and control groups: </B>50 mg/day of oral zinc sulfate (n = 28) versus control group with regular exercise and weight control (n = 25)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Outcomes reported in abstract of publication</B>
</P>
<P>Adiponectin, fasting blood glucose, insulin and insulin resistance, and lipid profile</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-05-18 12:50:15 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Run-in period:</B> 4 weeks</P>
<P>
<B>Study terminated before regular end (for benefit/because of adverse events): </B>no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2015-05-18 12:50:12 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication:</B> English</P>
<P>
<B>Commercial funding/non-commercial funding/other funding: </B>Yazd Diabetes Research Center</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-09-15 16:00:35 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "This study was conducted to assess the effect of zinc supplementation on serum adiponectin and insulin resistance in first degree relatives of diabetic patients."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-05-18 12:40:48 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We contacted the author on 16 April 2015 to request information about risk of bias. We are awaiting a reply</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BMI: body mass index<BR/>HOMA-IR: Homeostasis Model Assessment of Insulin Resistance</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-05-18 12:43:45 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Czernichow-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-18 12:43:45 +0200" MODIFIED_BY="Gudrun Paletta">
<P>RCT, but evaluated vitamin C, vitamin E, ß-carotene, selenium, and zinc or placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Czernichow-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>RCT, but evaluated a combination of antioxidants (vitamins C and E, ß-carotene, zinc and selenium) at nutritional doses or a placebo in metabolic syndrome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Islam-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Cross-sectional study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-18 12:43:51 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Kelishadi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-18 12:43:51 +0200" MODIFIED_BY="Gudrun Paletta">
<P>RCT, but only evaluated children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-18 12:43:48 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Kim-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-18 12:43:48 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-18 12:43:49 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Marchesini-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-18 12:43:49 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Case series study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-18 12:44:00 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Marreiro-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-18 12:44:00 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Controlled clinical trial and only evaluated children and adolescents</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-18 12:44:01 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Ramos-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-18 12:44:01 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-18 12:44:02 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Stewart-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-18 12:44:02 +0200" MODIFIED_BY="Gudrun Paletta">
<P>RCT, but evaluated vitamin B12</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Ranasinghe-2013">
<CHAR_STUDY_NAME MODIFIED="2015-05-18 12:44:21 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Zinc supplementation in pre-diabetes: study protocol for a randomised controlled trial</B>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Design: </B>single-centre, randomised, double-blind, placebo-controlled clinical trial</P>
<P>
<B>Setting:</B> Faculty of Medicine, University of Colombo, Sri Lanka</P>
<P>
<B>Sample size: </B>the number of participants required for determination of a 20% reduction of fasting plasma glucose in the treatment arm in comparison with the placebo arm at 90% power and 95% confidence interval with a dropout rate of 30% is 100 patients per arm. Hence, a total of 200 participants with prediabetes will be recruited for the study</P>
<P>
<B>Intention-to-treat analysis:</B> not reported</P>
<P>
<B>Follow-up: </B>12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria: </B>both genders between the ages of 18 and 60 years, eligible for the study through a screening test confirming the presence of prediabetes. Prediabetes is defined as the presence of fasting plasma glucose levels between 110 and 125 mg/dL or 2-hour post-oral glucose plasma glucose levels between 140 and 199 mg/dL, or both</P>
<P>
<B>Exclusion criteria: </B>on any other vitamin or mineral supplementation or the current use of a weight loss medicine or dietary modification; history of diabetes mellitus or any metabolic disease; alcohol consumption &gt; 20 g/day; presently having acute diseases or other untreated illness requiring treatment; impaired hepatic or renal functions; lactation, pregnancy or unwillingness to use an effective form of birth control for women of child-bearing years; history or presence of any condition that would endanger the individual's safety or affect the study result</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres:</B> 1</P>
<P>
<B>Treatment before study:</B> none</P>
<P>
<B>Titration period:</B> none<BR/>
</P>
<P>The treatment drug is a capsule containing elemental zinc 20 mg as the active ingredient; the placebo had a similar appearance, shape, weight, taste and colour as the zinc 20 mg capsule; the participants receive either 1 capsule of 20 mg zinc or an identical placebo daily, taken 1 hour before breakfast for a period of 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-18 15:15:52 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcomes:</B> the following biochemical assessments will be done at baseline, at stated intervals and at completion: fasting plasma glucose, oral glucose tolerance test, serum insulin, HbA1c, total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, and serum zinc. Furthermore, appetite will be evaluated using a visual analogue scale (VAS)</P>
<P>
<B>Secondary outcomes:</B> measurement of systolic (SBP) and diastolic blood pressure (DBP), anthropometric assessment such as body weight, height, body mass index (BMI), waist circumference (WC), hip circumference (HC) and waist:hip ratio (WHR), dietary assessment using a validated food frequency questionnaire (FFQ)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-18 12:44:54 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Not reported</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-05-14 14:02:08 +0200" MODIFIED_BY="[Empty name]">
<P>Dr Priyanga Ranasinghe: priyanga.ranasinghe@gmail.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-05-14 14:01:32 +0200" MODIFIED_BY="[Empty name]">
<P>Trial registration: Sri Lanka Clinical Trial Registry: SLCTR/2012/010</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>HDL: high-density lipoprotein<BR/>LDL: low-density lipoprotein</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-05-19 16:49:22 +0200" MODIFIED_BY="Bernd Richter">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-04-28 13:09:48 +0200" MODIFIED_BY="Bernd Richter" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-28 13:09:48 +0200" MODIFIED_BY="Bernd Richter" RESULT="YES" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006">
<DESCRIPTION>
<P>Quote from publication: "La aleatorización de los participantes para recibir sulfato de zinc o placebo se realizó mediante el azar simple"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-15 16:37:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marreiro-2006">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-26 02:35:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soheilykhah-2012">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-05-19 16:48:51 +0200" MODIFIED_BY="Bernd Richter" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-19 16:48:51 +0200" MODIFIED_BY="Bernd Richter" RESULT="YES" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006">
<DESCRIPTION>
<P>Quote from publication: "...con la selección de un sobre cerrado que contenía la opción A o B."<BR/>Quote from contact with the study author by email: "We used opaque and sealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-15 16:37:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marreiro-2006">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-26 02:36:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soheilykhah-2012">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-05-18 12:39:33 +0200" MODIFIED_BY="Gudrun Paletta" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-18 12:39:33 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006">
<DESCRIPTION>
<P>Quote from publication: "un ensayo clínico al azar, doble ciego, controlado con placebo"<BR/>Comment: the study drugs were double-blinded to both participants and investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-18 12:39:33 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006">
<DESCRIPTION>
<P>Quote from publication: "un ensayo clínico al azar, doble ciego, controlado con placebo"<BR/>Comment: the study drugs were double-blinded to both participants and investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-04-15 16:37:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marreiro-2006">
<DESCRIPTION>
<P>Quote from publication: "Both of the groups received pills identified by color...However, neither the researchers nor the patients knew which pill contained zinc."</P>
<P>Comment: the study drugs were double-blinded to both participants and investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-04-15 16:37:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marreiro-2006">
<DESCRIPTION>
<P>Quote from publication: "Both of the groups received pills identified by color...However, neither the researchers nor the patients knew which pill contained zinc."</P>
<P>Comment: the study drugs were double-blinded to both participants and investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-08-26 02:36:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soheilykhah-2012">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-08-26 02:36:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soheilykhah-2012">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-05-19 16:49:22 +0200" MODIFIED_BY="Bernd Richter" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-04-23 13:09:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006">
<DESCRIPTION>
<P>Quote from contact with author by email: "The study was triple blind, the patients received one capsule of 100 mg/day of zinc sulfate orally daily or placebo capsule approved with identical presentation. Neither the researchers, nor the patients nor the person who performed the statistical analyses knew which group participants were allocated."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-19 16:49:22 +0200" MODIFIED_BY="Bernd Richter" RESULT="YES" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006">
<DESCRIPTION>
<P>Quote from contact with author by email: "The study was triple blind, the patients received one capsule of 100 mg/day of zinc sulfate orally daily or placebo capsule approved with identical presentation. Neither the researchers, nor the patients nor the person who performed the statistical analyses knew which group participants were allocated."</P>
<P>Quote from contact with the study author by email: "The blinding of the outcome assessors was for both objective and subjective outcomes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-04-15 16:37:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marreiro-2006">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-04-15 16:37:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marreiro-2006">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-26 02:36:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soheilykhah-2012">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-08-26 02:36:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soheilykhah-2012">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-04-15 16:37:34 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-08 16:23:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006">
<DESCRIPTION>
<P>Comment: all participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-05-08 16:23:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006">
<DESCRIPTION>
<P>Comment: all participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-04-15 16:37:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marreiro-2006">
<DESCRIPTION>
<P>Comment: all participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-04-15 16:37:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marreiro-2006">
<DESCRIPTION>
<P>Comment: all participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-04-15 16:37:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soheilykhah-2012">
<DESCRIPTION>
<P>Quote from publication: "In this randomized clinical control study 58 subjects from first degree relatives of diabetic patients...of these, 53 subjects."</P>
<P>Comment: low attrition rate with probably only minor influence on outcome measures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-04-15 16:37:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soheilykhah-2012">
<DESCRIPTION>
<P>Quote from publication: "In this randomized clinical control study 58 subjects from first degree relatives of diabetic patients...of these, 53 subjects."</P>
<P>Comment: low attrition rate with probably only minor influence on outcome measures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-04-15 16:37:34 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-15 16:36:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006">
<DESCRIPTION>
<P>Comment: none detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-15 16:37:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marreiro-2006">
<DESCRIPTION>
<P>Comment: none detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-15 16:37:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soheilykhah-2012">
<DESCRIPTION>
<P>Comment: none detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-04-23 13:09:40 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-23 13:09:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006">
<DESCRIPTION>
<P>Quote from contact with author by email: "There was no conflict of interest."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-15 16:37:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marreiro-2006">
<DESCRIPTION>
<P>Comment: none detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-15 16:37:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soheilykhah-2012">
<DESCRIPTION>
<P>Comment: none detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-10-02 08:46:52 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-05-19 16:55:32 +0200" MODIFIED_BY="Bernd Richter">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-05-19 16:55:32 +0200" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2015-04-09 17:15:58 +0200" MODIFIED_BY="Bernd Richter">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>
<B>Zinc supplementation for the prevention of type 2 diabetes mellitus</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>
<B>Population: </B>non-diabetic adults with insulin resistance</P>
<P>
<B>Settings: </B>not specified/outpatients</P>
<P>
<B>Intervention: </B>zinc supplementation</P>
<P>
<B>Comparison: </B>placebo or exercise</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Placebo or exercise</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Zinc supplementation</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Incidence of type 2 diabetes mellitus</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Diabetic complications</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Health-related quality of life</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Socioeconomic effects</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-05-19 16:55:58 +0200" MODIFIED_BY="Bernd Richter">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-05-19 16:55:58 +0200" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2014-05-08 16:46:10 +0200" MODIFIED_BY="G P">Overview of study populations</TITLE>
<TABLE COLS="10" ROWS="13">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH VALIGN="TOP">
<P>Sample size<SUP>a</SUP>
</P>
</TH>
<TH VALIGN="TOP">
<P>Screened/eligible<BR/>[N]</P>
</TH>
<TH VALIGN="TOP">
<P>Randomised<BR/>[N]</P>
</TH>
<TH VALIGN="TOP">
<P>ITT<BR/>[N]</P>
</TH>
<TH VALIGN="TOP">
<P>Analysed<BR/>[N]</P>
</TH>
<TH VALIGN="TOP">
<P>Finishing study<BR/>[N]</P>
</TH>
<TH VALIGN="TOP">
<P>Randomised finishing study<BR/>[%]</P>
</TH>
<TH VALIGN="TOP">
<P>Follow-up time<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(1) Gómez-García 2006</P>
</TH>
<TD VALIGN="TOP">
<P>I: 100 mg/day zinc sulfate</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>12<BR/>(6 participants per group; 80% power)<BR/>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>1 month</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(2) Marreiro 2006</P>
</TH>
<TD VALIGN="TOP">
<P>I: 30 mg/day zinc amino chelate<BR/>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>1 month</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(3) Soheilykhah 2012</P>
</TH>
<TD VALIGN="TOP">
<P>I: 50 mg/day zinc sulfate</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>12 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: regular exercise and weight control</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TD VALIGN="TOP">
<P>58</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>53</P>
</TD>
<TD VALIGN="TOP">
<P>53</P>
</TD>
<TD VALIGN="TOP">
<P>91.4</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>
<I>Grand total</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>
<B>All interventions</B>
</I>
</P>
</TH>
<TD COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P/>
</TD>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>63</I>
</P>
</TH>
<TD COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P/>
</TD>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>63</I>
</P>
</TH>
<TD COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<I>
<B>All c</B>omparator<B>s</B>
</I>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>60</I>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>60</I>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<I>
<B>All interventions and c</B>omparator<B>s</B>
</I>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>128</I>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>123</I>
</P>
</TH>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>According to power calculation in study publication or report<BR/>
<SUP>b</SUP>Duration of intervention and/or follow-up under randomised conditions until end of study</P>
<P>"-" denotes not reported</P>
<P>C: comparator; I: intervention; ITT: intention-to-treat.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-05-14 15:27:00 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-05-14 15:26:47 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Zinc supplementation versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2015-04-13 16:37:47 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="16.249163038960234" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="28" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HOMA-IR</NAME>
<GROUP_LABEL_1>Zinc supplementation</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Zinc supplementation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.01" MODIFIED="2015-04-13 16:28:42 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>HOMA-IR</NAME>
<CONT_DATA CI_END="1.0817972208623938" CI_START="-1.281797220862395" EFFECT_SIZE="-0.10000000000000053" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="4.4" MODIFIED="2014-03-07 18:44:59 +0100" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="1.7" SD_2="2.7" SE="0.602968845440151" STUDY_ID="STD-Marreiro-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2015-05-14 15:26:47 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="59.93022084577825" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="175" TOTAL_2="175" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Lipids</NAME>
<GROUP_LABEL_1>Zinc supplementation</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Zinc supplementation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2015-04-13 16:29:59 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Total cholesterol</NAME>
<CONT_DATA CI_END="28.961317294399347" CI_START="-11.961317294399347" EFFECT_SIZE="8.5" ESTIMABLE="YES" MEAN_1="192.6" MEAN_2="184.1" MODIFIED="2015-04-13 16:27:55 +0200" MODIFIED_BY="Bernd Richter" ORDER="52" SD_1="38.1" SD_2="40.0" SE="10.439639430007697" STUDY_ID="STD-Marreiro-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" MODIFIED="2015-04-13 16:30:04 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>Total cholesterol</NAME>
<CONT_DATA CI_END="15.664483946269026" CI_START="-39.264483946268996" EFFECT_SIZE="-11.799999999999983" ESTIMABLE="YES" MEAN_1="151.4" MEAN_2="163.2" MODIFIED="2014-03-07 17:12:30 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="16.7" SD_2="33.1" SE="14.01274929687757" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.03" MODIFIED="2015-05-14 15:26:22 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>HDL cholesterol</NAME>
<CONT_DATA CI_END="0.3607401678061546" CI_START="-15.760740167806146" EFFECT_SIZE="-7.699999999999996" ESTIMABLE="YES" MEAN_1="35.1" MEAN_2="42.8" MODIFIED="2014-03-07 17:13:08 +0100" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="6.4" SD_2="8.8" SE="4.112698106387791" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.04" MODIFIED="2015-05-14 15:26:27 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>HDL cholesterol</NAME>
<CONT_DATA CI_END="7.660061323133771" CI_START="-4.860061323133774" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" MEAN_1="44.1" MEAN_2="42.7" MODIFIED="2015-04-13 16:28:04 +0200" MODIFIED_BY="Bernd Richter" ORDER="55" SD_1="10.8" SD_2="13.0" SE="3.193967528236405" STUDY_ID="STD-Marreiro-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.05" MODIFIED="2015-05-14 15:26:32 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>LDL cholesterol</NAME>
<CONT_DATA CI_END="24.750918875058016" CI_START="-11.550918875058027" EFFECT_SIZE="6.599999999999994" ESTIMABLE="YES" MEAN_1="124.3" MEAN_2="117.7" MODIFIED="2015-04-13 16:28:01 +0200" MODIFIED_BY="Bernd Richter" ORDER="54" SD_1="34.9" SD_2="34.4" SE="9.260843065602304" STUDY_ID="STD-Marreiro-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.06" MODIFIED="2015-05-14 15:26:37 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>LDL cholesterol</NAME>
<CONT_DATA CI_END="25.063094157508374" CI_START="-41.46309415750838" EFFECT_SIZE="-8.200000000000003" ESTIMABLE="YES" MEAN_1="91.6" MEAN_2="99.8" MODIFIED="2014-03-07 17:13:42 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="16.9" SD_2="41.6" SE="16.97127825811261" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.07" MODIFIED="2015-05-14 15:26:41 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>VLDL cholesterol</NAME>
<CONT_DATA CI_END="5.87731636536105" CI_START="-6.077316365361046" EFFECT_SIZE="-0.09999999999999787" ESTIMABLE="YES" MEAN_1="23.6" MEAN_2="23.7" MODIFIED="2015-04-13 16:28:11 +0200" MODIFIED_BY="Bernd Richter" ORDER="53" SD_1="10.9" SD_2="11.9" SE="3.0497072459031678" STUDY_ID="STD-Marreiro-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.08" MODIFIED="2015-05-14 15:26:47 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>VLDL lipoprotein</NAME>
<CONT_DATA CI_END="2.54725825991399" CI_START="-16.147258259913983" EFFECT_SIZE="-6.799999999999997" ESTIMABLE="YES" MEAN_1="24.6" MEAN_2="31.4" MODIFIED="2014-03-07 17:14:38 +0100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="6.0" SD_2="11.1" SE="4.76909694955824" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.09" MODIFIED="2015-04-13 16:31:01 +0200" MODIFIED_BY="Bernd Richter" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Triglycerides</NAME>
<CONT_DATA CI_END="31.432300960154375" CI_START="-27.232300960154358" EFFECT_SIZE="2.1000000000000085" ESTIMABLE="YES" MEAN_1="121.2" MEAN_2="119.1" MODIFIED="2015-04-13 16:28:07 +0200" MODIFIED_BY="Bernd Richter" ORDER="51" SD_1="51.8" SD_2="59.9" SE="14.965734672434705" STUDY_ID="STD-Marreiro-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.10" MODIFIED="2015-04-13 16:31:01 +0200" MODIFIED_BY="Bernd Richter" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>Triglycerides </NAME>
<CONT_DATA CI_END="23.549309085354984" CI_START="-41.74930908535497" EFFECT_SIZE="-9.099999999999994" ESTIMABLE="YES" MEAN_1="123.4" MEAN_2="132.5" MODIFIED="2014-03-07 17:14:21 +0100" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="30.2" SD_2="32.1" SE="16.658116854640475" STUDY_ID="STD-G_x00f3_mez_x002d_Garc_x00ed_a-2006" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-05-14 15:27:00 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Zinc supplementation versus exercise</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2015-04-13 16:37:27 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HOMA-IR</NAME>
<GROUP_LABEL_1>Zinc supplementation</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours zinc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours exercise</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.48459522473520533" CI_START="-1.0245952247352053" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.81" MODIFIED="2015-04-13 16:37:27 +0200" MODIFIED_BY="Bernd Richter" ORDER="94" SD_1="1.34" SD_2="1.45" SE="0.38500463819098524" STUDY_ID="STD-Soheilykhah-2012" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2015-05-14 15:27:00 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="63.04" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="112" TOTAL_2="100" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Lipids</NAME>
<GROUP_LABEL_1>Zinc supplementation</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Zinc supplementation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control group</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.01" MODIFIED="2015-04-15 16:39:02 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Total cholesterol</NAME>
<CONT_DATA CI_END="7.317937092909389" CI_START="-27.83793709290937" EFFECT_SIZE="-10.259999999999991" ESTIMABLE="YES" MEAN_1="189.5" MEAN_2="199.76" MODIFIED="2014-08-26 03:55:07 +0200" MODIFIED_BY="[Empty name]" ORDER="97" SD_1="34.26" SD_2="31.03" SE="8.968500049777395" STUDY_ID="STD-Soheilykhah-2012" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.02" MODIFIED="2015-05-14 15:26:56 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>HDL cholesterol</NAME>
<CONT_DATA CI_END="7.112312457838076" CI_START="-2.4723124578380755" EFFECT_SIZE="2.3200000000000003" ESTIMABLE="YES" MEAN_1="42.57" MEAN_2="40.25" MODIFIED="2014-08-26 03:56:22 +0200" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="9.33" SD_2="8.47" SE="2.445102305776649" STUDY_ID="STD-Soheilykhah-2012" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.03" MODIFIED="2015-05-14 15:27:00 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>LDL cholesterol</NAME>
<CONT_DATA CI_END="5.018668549324097" CI_START="-19.718668549324114" EFFECT_SIZE="-7.3500000000000085" ESTIMABLE="YES" MEAN_1="119.71" MEAN_2="127.06" MODIFIED="2014-08-26 03:56:49 +0200" MODIFIED_BY="[Empty name]" ORDER="100" SD_1="24.5" SD_2="21.44" SE="6.310661138105896" STUDY_ID="STD-Soheilykhah-2012" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.04" MODIFIED="2015-04-15 16:39:02 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Triglycerides</NAME>
<CONT_DATA CI_END="-10.473541772353808" CI_START="-49.22645822764623" EFFECT_SIZE="-29.850000000000023" ESTIMABLE="YES" MEAN_1="130.39" MEAN_2="160.24" MODIFIED="2014-08-26 03:55:57 +0200" MODIFIED_BY="[Empty name]" ORDER="98" SD_1="34.4" SD_2="37.24" SE="9.886129735283527" STUDY_ID="STD-Soheilykhah-2012" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-05-19 16:49:23 +0200" MODIFIED_BY="Bernd Richter">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-05-18 15:14:25 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8sAAAOGCAYAAADbNwIdAACAAElEQVR42uydD4QV3///PyRJkiVZ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-05-19 16:49:23 +0200" MODIFIED_BY="Bernd Richter" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtYAAAFLCAMAAADF3jv0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-05-19 16:49:23 +0200" MODIFIED_BY="Bernd Richter" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAbMAAAInCAIAAACdkCAYAAAdcklEQVR42u3dsY4lRZqG4ZKQEEYb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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-05-19 16:54:49 +0200" MODIFIED_BY="Bernd Richter">
<APPENDIX ID="APP-01" MODIFIED="2015-05-14 15:28:54 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-04-08 12:07:55 +0200" MODIFIED_BY="Bernd Richter">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-14 15:28:54 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="10">
<TR>
<TH>
<P>
<I>
<B>The Cochrane Library</B>
</I>
</P>
</TH>
</TR>
<TR>
<TD>
<P>#1 [mh Zinc/AD,AE,ST,TU,TH]<BR/>#2 (zinc near/4 supplement*):ti,ab,kw<BR/>#3 #1 or #2<BR/>#4 [mh "Glucose tolerance test"]<BR/>#5 [mh "Glucose intolerance"]<BR/>#6 [mh "Diabetes mellitus"/PC]<BR/>#7 [mh "Insulin resistance"]<BR/>#8 [mh "Metabolic syndrome X"]<BR/>#9 [mh "Prediabetic state"]<BR/>#10 (glucose near/4 (intolerance or tolerance test*)):ti,ab,kw<BR/>#11 (impaired and (fasting near/4 (glucose or glycemia* or glycaemia*))):ti,ab,kw<BR/>#12 (impaired and (glucose near/4 (toleran* or stat* or respons* or control* or regul* or metabol* or homeost*))):ti,ab,kw<BR/>#13 (reduced and (glucose near/4 (metab* or toleran*))):ti,ab,kw<BR/>#14 (praediabet* or prae diabet* or prediabet* or pre diabet*):ti,ab,kw<BR/>#15 (metabolic syndrom* or syndrome X):ti,ab,kw<BR/>#16 ((borderline or mild) near/4 diabet*):ti,ab,kw<BR/>#17 (insulin* near/4 resistan*):ti,ab,kw<BR/>#18 (((impaired or reduced) near/4 insulin) near/4 secret*):ti,ab,kw<BR/>#19 {or #4-#18}<BR/>#20 #3 and #19<BR/>
</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>MEDLINE (via Ovid SP)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1 (zinc adj3 supplement*).tw,ot.<BR/>2 exp Zinc/ad, ae, st, tu, th [Administration &amp; Dosage, Adverse Effects, Standards, Therapeutic Use, Therapy]<BR/>3 1 or 2<BR/>4 exp Glucose Tolerance Test/ or exp Glucose Intolerance/<BR/>5 exp Diabetes Mellitus, Type 2/pc [Prevention &amp; Control]<BR/>6 exp Insulin Resistance/<BR/>7 exp Metabolic Syndrome X/<BR/>8 exp Prediabetic State/<BR/>9 (glucose adj3 (intolerance or tolerance test*)).tw,ot.<BR/>10 (impaired fasting adj3 (glucose or glyc?emia*)).tw,ot.<BR/>11 (impaired glucose adj3 (toleran* or stat* or respons* or control* or regul* or metab* or homeost*)).tw,ot.<BR/>12 (reduced glucose adj3 (metab* or toleran*)).tw,ot.<BR/>13 (pr?ediabet* or pr?e diabet*).tw,ot.<BR/>14 (metabolic syndrom* or syndrome X).tw,ot.<BR/>15 ((borderline or mild) adj3 diabet*).tw,ot.<BR/>16 insulin resistan*.tw,ot.<BR/>17 ((impaired or reduced) adj3 insulin secret*).tw,ot.<BR/>18 or/4-17<BR/>19 3 and 18</P>
<P>
<I>[20-30: </I>
<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>
<I> RCT filter - max. sensitivity version]</I>
</P>
<P>20 randomized controlled trial.pt.<BR/>21 controlled clinical trial.pt.<BR/>22 randomized.ab.<BR/>23 placebo.ab.<BR/>24 randomly.ab.<BR/>25 drug therapy.fs.<BR/>26 trial.ab.<BR/>27 groups.ab.<BR/>28 or/20-27<BR/>29 exp animals/ not humans/<BR/>30 28 not 29<BR/>31 19 and 30</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>EMBASE (via Ovid SP)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1 exp zinc/ae, do, dt, th [Adverse Drug Reaction, Drug Dose, Drug Therapy, Therapy]<BR/>2 (zinc adj3 supplement*).tw,ot.<BR/>3 1 or 2<BR/>4 exp glucose tolerance test/<BR/>5 exp glucose intolerance/<BR/>6 exp non insulin dependent diabetes mellitus/pc [Prevention]<BR/>7 exp insulin resistance/<BR/>8 exp metabolic syndrome X/<BR/>9 exp impaired glucose tolerance/<BR/>10 (glucose adj3 (intolerance or tolerance test*)).tw,ot.<BR/>11 (impaired fasting adj3 (glucose or glyc?emia*)).tw,ot.<BR/>12 (impaired glucose adj3 (toleran* or stat* or respons* or control* or regul* or metab* or homeost*)).tw,ot.<BR/>13 (reduced glucose adj3 (metab* or toleran*)).tw,ot.<BR/>14 (pr?e diabet* or pr?ediabet*).tw,ot.<BR/>15 (metabolic syndrom* or syndrom* X).tw,ot.<BR/>16 ((borderline or mild) adj3 diabet*).tw,ot.<BR/>17 insulin resistan*.tw,ot.<BR/>18 ((impaired or reduced) adj3 insulin secret*).tw,ot.<BR/>19 or/4-18<BR/>20 3 and 19</P>
<P>
<I>[21: </I>
<LINK REF="REF-Wong-2006" TYPE="REFERENCE">Wong 2006</LINK>
<I> "treatment studies" filter - SDSSGS version]</I>
</P>
<P>21 random*.tw. or clinical trial*.mp. or exp treatment outcome/<BR/>22 20 and 21</P>
</TD>
</TR>
<TR>
<TH>
<P>LILACS (via IAHx)</P>
</TH>
</TR>
<TR>
<TD>
<P>zinc AND diabet*</P>
</TD>
</TR>
<TR>
<TH>
<P>ICTRP Search Platform (Standard search)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<I>[searched as one string]</I>
<BR/>zinc* AND glucose OR<BR/>zinc* AND diabet* OR<BR/>zinc* AND insulin OR<BR/>zinc* AND metabol* OR<BR/>zinc* AND prediabet* OR<BR/>zinc* AND glycemia OR<BR/>zinc* AND glycaemia</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-05-19 16:53:47 +0200" MODIFIED_BY="Bernd Richter" NO="2">
<TITLE MODIFIED="2014-04-28 14:55:00 +0200" MODIFIED_BY="G P">Description of interventions</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-19 16:53:47 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="5" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Intervention(s) [route, frequency, total dose/day]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Adequate<SUP>a</SUP> intervention</P>
<P>[Yes/No]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Comparator(s) [route, frequency, total dose/day]<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Adequate<SUP>a</SUP> comparator</P>
<P>[Yes/No]</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Gómez-García 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100 mg/day zinc sulfate orally</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Marreiro 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 mg/day zinc amino chelate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Soheilykhah 2012</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50 mg/day zinc sulfate orally</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Regular exercise and weight control</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P>
<SUP>a</SUP>The term 'adequate' refers to sufficient use of the intervention/comparator with regard to dose, dose escalation, dosing scheme, provision for contraindications and other features necessary to establish a fair contrast between intervention and comparator</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-05-19 16:53:40 +0200" MODIFIED_BY="Bernd Richter" NO="3">
<TITLE MODIFIED="2014-06-11 12:34:31 +0200" MODIFIED_BY="G P">Baseline characteristics (I)</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-19 16:53:40 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="9" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Intervention(s) and<BR/>comparator(s)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Duration of intervention<BR/>(duration of follow-up)<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Description of participants</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Study period<BR/>[year to year]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Country</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Setting</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Ethnic groups<BR/>[%]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Duration of condition<BR/>[mean years (SD)]</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Gómez-García 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1 month</P>
<P>(1 month)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Obese men</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Mexico</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Medical research unit</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Marreiro 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1 month</P>
<P>(1 month)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Obese women</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Brazil</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outpatients (hospital clinics)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Soheilykhah 2012</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>12 weeks</P>
<P>(12 weeks)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Overweight or obese participants</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>2009 to 2010</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Iran</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Yazd Diabetes Research Center</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: regular exercise and weight control</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="9" VALIGN="TOP">
<P>"-" denotes not reported</P>
<P>C: comparator; I: intervention; SD: standard deviation</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2015-05-19 16:53:55 +0200" MODIFIED_BY="Bernd Richter" NO="4">
<TITLE MODIFIED="2014-04-28 14:55:07 +0200" MODIFIED_BY="G P">Baseline characteristics (II)</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-19 16:53:55 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="8" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Intervention(s) and<BR/>comparator(s)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Sex<BR/>[female %]<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Age<BR/>[mean/range years (SD),<BR/>or as reported]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>HbA1c<BR/>[%]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>BMI<BR/>[mean kg/m²<BR/>(SD)]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Co-medications/<BR/>Co-interventions</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Comorbidities</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Gómez-García 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21.8 (2.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30.7 (2.6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No co-medications/co-interventions</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Obesity</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25.1 (4.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30.5 (3.9)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Marreiro 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35.5 (6.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35.8 (2.2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No co-medications/co-interventions</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Obesity</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33.9 (5.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36.5 (2.5)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Soheilykhah 2012</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>57<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>37.6 (7.4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>28.8 (3.5)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No co-medications/co-interventions</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>BMI more than 25 kg/m² with normal 75 g OGTT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: regular exercise and weight control</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="8" VALIGN="TOP">
<P>"-" denotes not reported</P>
<P>
<SUP>a</SUP>Refers to 53/58 participants completing the study</P>
<P>BMI: body mass index; C: comparator; HbA1c: glycosylated haemoglobin A1c; I: intervention; OGTT: oral glucose tolerance test; SD: standard deviation</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2015-05-19 16:54:01 +0200" MODIFIED_BY="Bernd Richter" NO="5">
<TITLE MODIFIED="2015-04-09 13:39:12 +0200" MODIFIED_BY="Bernd Richter">Matrix of study endpoints (publications and trial documents)</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-19 16:54:01 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="4" ROWS="11">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Endpoints quoted in trial document(s)<BR/>(ClinicalTrials.gov, FDA/EMA document, manufacturer's website, published design paper)<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Endpoints quoted in publication(s)<SUP>b,c</SUP>
<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Endpoints quoted in <U>abstract</U> of publication(s)<SUP>b,c</SUP>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Gómez-García 2006</P>
</TH>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Source:</B> N/T</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s)</B>:</P>
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s)</B>:</P>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B>
</P>
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B>
</P>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s)</B>:</P>
<P>Insulin sensitivity, leptin levels, biochemical profile and androgens</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s)</B>:</P>
<P>Insulin sensitivity, leptin levels, biochemical profile and androgens</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Marreiro 2006</P>
</TH>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Source:</B> N/T</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s)</B>:</P>
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s)</B>:</P>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B>
</P>
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B>
</P>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s)</B>:</P>
<P>BMI, fasting glucose and zinc concentration in plasma, insulin, HOMA-IR, leptin, waist circumference, waist-to-hip ratio, percentage of fat</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s)</B>:</P>
<P>BMI, fasting glucose, zinc concentration in plasma, urine and erythrocytes, insulin, HOMA-IR, leptin, glucose</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Soheilykhah 2012</P>
</TH>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Source:</B> N/T</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s)</B>:</P>
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s)</B>:</P>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B>
</P>
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B>
</P>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s)</B>:</P>
<P>Adiponectin, fasting blood glucose, insulin and insulin resistance and lipid profile</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s)</B>:</P>
<P>Adiponectin, fasting blood glucose, insulin and insulin resistance and lipid profile</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4" VALIGN="TOP">
<P>- denotes not reported</P>
<P>
<SUP>a</SUP>Trial document(s) refers to all available information from published design papers and sources other than regular publications (e.g. FDA/EMA documents, manufacturer's websites, trial registers).<BR/>
<SUP>b</SUP>Publication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion documents or multiple reports of a primary study).<BR/>
<SUP>c</SUP>Other outcome measures refer to all outcomes not specified as primary or secondary outcome measures.<BR/>
</P>
<P>BMI: body mass index; EMA: European Medicines Agency; FDA: Food and Drug Administration (US); HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; N/A: not applicable; N/T: no trial document available</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2015-05-19 16:54:09 +0200" MODIFIED_BY="Bernd Richter" NO="6">
<TITLE MODIFIED="2015-04-09 15:23:58 +0200" MODIFIED_BY="Bernd Richter">Examination of outcome reporting bias according to ORBIT classification</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-19 16:54:09 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="6" ROWS="5">
<TR>
<TH VALIGN="TOP">
<P/>
<P/>
</TH>
<TH VALIGN="TOP">
<P>Outcome</P>
</TH>
<TH VALIGN="TOP">
<P>High risk of bias<BR/>(category A)<SUP>a</SUP>
</P>
</TH>
<TH VALIGN="TOP">
<P>High risk of bias<BR/>(category D)<SUP>b</SUP>
</P>
</TH>
<TH VALIGN="TOP">
<P>High risk of bias<BR/>(category E)<SUP>c</SUP>
</P>
</TH>
<TH VALIGN="TOP">
<P>High risk of bias<BR/>(category G)<SUP>d</SUP>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Gómez-García 2006</P>
</TH>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Marreiro 2006</P>
</TH>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>Soheilykhah 2012</B>
</P>
</TH>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<SUP>a</SUP>Clear that outcome was measured and analysed; trial report states that outcome was analysed but only reports that result was not significant (Classification 'A', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>).<BR/>
<SUP>b</SUP>Clear that outcome was measured and analysed; trial report states that outcome was analysed but no results reported (Classification 'D', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>).<BR/>
<SUP>c</SUP>Clear that outcome was measured; clear that outcome was measured but not necessarily analysed; judgement says likely to have been analysed but not reported because of non-significant results (Classification 'E', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>).<BR/>
<SUP>d</SUP>Unclear whether the outcome was measured; not mentioned but clinical judgement says likely to have been measured and analysed but not reported on the basis of non-significant results (Classification 'G', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>).</P>
<P>N/A: not applicable</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2015-05-19 16:54:17 +0200" MODIFIED_BY="Bernd Richter" NO="7">
<TITLE MODIFIED="2015-04-09 15:24:25 +0200" MODIFIED_BY="Bernd Richter">Definition of endpoint measurement</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-19 16:54:17 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="9" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Incidence of type 2<BR/>diabetes mellitus</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Insulin<BR/>resistance</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Diabetic<BR/>complications</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>All-cause<BR/>mortality</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Health-related<BR/>quality of life</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Socioeconomic<BR/>effects</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Lipid levels</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Severe/serious<BR/>adverse events</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Gómez-García 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Insulin sensitivity measured by the glucose clamp technique</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Total cholesterol, HDL cholesterol, triglycerides measured by enzymatic methods; LDL cholesterol was estimated by the Friedewald formula and the very low density lipoproteins were calculated by triglycerides/5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Marreiro 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>HOMA-IR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Soheilykhah 2012</B>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>HOMA-IR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="9" VALIGN="TOP">
<P>HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; N/I: not investigated</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2015-05-19 16:54:24 +0200" MODIFIED_BY="Bernd Richter" NO="8">
<TITLE MODIFIED="2014-04-28 14:55:45 +0200" MODIFIED_BY="G P">Adverse events (I)</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-19 16:54:24 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="9" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Intervention(s)<BR/>and<BR/>comparator(s)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants included<BR/>in analysis<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Deaths<BR/>[N]<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Deaths<BR/>[%]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>All adverse<BR/>events<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>All adverse<BR/>events<BR/>[%]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Severe/serious<BR/>adverse events<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Severe/serious<BR/>adverse events<BR/>[%]</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Gómez-García 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Marreiro 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Soheilykhah 2012</B>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="9" VALIGN="TOP">
<P>"-" denotes not reported</P>
<P>C: comparator; I: intervention</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2015-05-19 16:54:30 +0200" MODIFIED_BY="Bernd Richter" NO="9">
<TITLE MODIFIED="2014-04-28 14:55:45 +0200" MODIFIED_BY="G P">Adverse events (II)</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-19 16:54:30 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="9" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Intervention(s)<BR/>and<BR/>comparator(s)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants included<BR/>in analysis<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Discontinued study<BR/>due to adverse events<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Discontinued study<BR/>due to adverse events<BR/>[%]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Hospitalisation<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Hospitalisation<BR/>[%]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Outpatient<BR/>treatment<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Outpatient<BR/>treatment<BR/>[%]</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Gómez-García 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Marreiro 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Soheilykhah 2012</B>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="9" VALIGN="TOP">
<P>"-" denotes not reported</P>
<P>C: comparator; I: intervention</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-10" MODIFIED="2015-05-19 16:54:49 +0200" MODIFIED_BY="Bernd Richter" NO="10">
<TITLE MODIFIED="2014-05-08 15:15:01 +0200" MODIFIED_BY="G P">Adverse events (III)</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-19 16:54:49 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="6" ROWS="8">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Intervention(s)<BR/>and<BR/>comparator(s)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants included<BR/>in analysis<BR/>[N]</P>
</TH>
<TH VALIGN="TOP">
<P>Specific adverse<BR/>events<BR/>[description]</P>
</TH>
<TH VALIGN="TOP">
<P>Specific adverse<BR/>events<BR/>[N participants]</P>
</TH>
<TH VALIGN="TOP">
<P>Specific adverse<BR/>events<BR/>[% participants]</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Gómez-García 2006</P>
</TH>
<TD VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Marreiro 2006</P>
</TH>
<TD VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>
<B>Soheilykhah 2012</B>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: zinc</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>"-" denotes not reported</P>
<P>C: comparator; I: intervention</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-11" MODIFIED="2015-05-19 16:54:47 +0200" MODIFIED_BY="Bernd Richter" NO="11">
<TITLE MODIFIED="2014-04-28 14:55:45 +0200" MODIFIED_BY="G P">Survey of authors providing information on included trials</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-19 16:54:47 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="5" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Study author contacted<BR/>
<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Study author replied<BR/>
<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Study author asked for additional information<BR/>[short summary]<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Study author provided data<BR/>[short summary]<BR/>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Gómez-García 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 April 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 April 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<OL>
<LI>Other RCT dealing with zinc and prevention of type 2 diabetes mellitus</LI>
<LI>Setting</LI>
<LI>Blinding</LI>
<LI>Conflict of interest</LI>
<LI>Exclusion criteria</LI>
<LI>Intention-to-treat analysis</LI>
<LI>Treatment before study</LI>
<LI>Allocation concealment</LI>
</OL>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<OL>
<LI>No</LI>
<LI>Medical Research Unit in Clinical Epidemiology, Hospital of Specialties, West National Medical Center of the Mexican Institute of Social Security (Guadalajara, Mexico)</LI>
<LI>The study was triple-blind, the participants received 1 capsule of 100 mg/day of zinc sulfate orally daily or a placebo capsule of identical appearance. Neither the researchers, nor the participants nor the person who performed the statistical analyses knew which group participants were allocated to. The blinding of outcome assessors was done for both objective and subjective outcomes</LI>
<LI>There was no conflict of interest</LI>
<LI>The exclusion criterion was the intake of any medication with an effect on the metabolism of carbohydrates, lipids, zinc, or insulin during the intervention. However, no participant had to be excluded from the study</LI>
<LI>An intention-to-treat analysis was contemplated, however, no participant had to be excluded from the study</LI>
<LI>The volunteers did not ingest any treatment at least in the month preceding the study</LI>
<LI>Opaque and sealed envelopes</LI>
</OL>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Marreiro 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 April 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>We are awaiting a reply</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Soheilykhah 2012</B>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 April 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>We are awaiting a reply</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P>N/A: not applicable; RCT: randomised controlled trial</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 completed studies (4 publications) included in qualitative synthesis&lt;/p&gt;" WIDTH="294">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies (5 publications) included&lt;/p&gt;" WIDTH="280">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 included study (1&lt;span&gt; publication&lt;/span&gt;) from previous (2007) version of review&lt;/p&gt;" WIDTH="152"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;14 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="332">
<FLOWCHARTBOX TEXT="&lt;p&gt;132 records screened&lt;/p&gt;" WIDTH="185">
<FLOWCHARTBOX TEXT="&lt;p&gt;132 records after duplicates removed&lt;/p&gt;" WIDTH="303">
<FLOWCHARTBOX TEXT="&lt;p&gt;141 records identified through database searching&lt;/p&gt;&lt;p&gt;The Cochrane Library: n = 20&lt;br&gt;MEDLINE: n = 21&lt;br&gt;EMBASE: n = 43&lt;br&gt;ICTRP Search Portal: n = 40&lt;br&gt;LILACS: n = 17&lt;/p&gt;" WIDTH="169"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through non-database sources (contacts with experts, manufacturers, handsearching of literature)&lt;/p&gt;" WIDTH="522"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;118 non-relevant records excluded (title/abstract)&lt;/p&gt;" WIDTH="217"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;9 full-text articles excluded&lt;/p&gt;&lt;p&gt;Reasons:&lt;/p&gt;&lt;p&gt;1. RCT, but evaluated vitamins or children only (n = 4)&lt;br&gt;2. Controlled clinical trial (n = 3)&lt;br&gt;3. Case series (n = 1)&lt;br&gt;4. Cross-sectional study (n = 1)&lt;/p&gt;" WIDTH="254"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 potentially relevant ongoing trial&lt;/p&gt;" WIDTH="278"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>